Page last updated: 2024-08-16

pioglitazone and rosiglitazone

pioglitazone has been researched along with rosiglitazone in 618 studies

Research

Studies (618)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	16 (2.59)	18.2507
2000's	337 (54.53)	29.6817
2010's	248 (40.13)	24.3611
2020's	17 (2.75)	2.80

Authors

Authors	Studies
Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL	1
Beck, KD; Cobb, JE; Correa, ID; Cowan, DJ; Kliewer, SA; Lehmann, JM; Moore, LB; Prakash, SR; Wiethe, RW; Willson, TM	1
Buckle, DR; Cantello, BC; Chapman, H; Clapham, JC; Coyle, PJ; Haigh, D; Hindley, RM; Holder, JC; Kallender, H; Latter, AJ; Lawrie, KW; Mossakowska, D; Murphy, GJ; Roxbee Cox, L; Smith, SA; Young, PW	1
Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM	1
Adkison, KK; Blanchard, SG; Henke, BR; Leesnitzer, LM; Mook, RA; Plunket, KD; Ray, JA; Roberson, C; Unwalla, R; Willson, TM	1
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM	1
Ayscue, AH; Henke, BR; Lambert, MH; Leesnitzer, LM; Liu, KG; Oliver, WR; Plunket, KD; Sternbach, DD; Willson, TM; Xu, HE	1
Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L	1
Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P	1
Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L	1
Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T	1
Etoh, K; Fujieda, H; Hattori, Y; Imagawa, M; Kohda, K; Miyata, N; Nakagawa, H; Nishizuka, M; Suzuki, T; Usui, S	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Avery, MA; Benson, SC; Chittiboyina, AG; Desai, PV; Ho, CI; Kurtz, TW; Mizuno, CS; Patny, A; Pershadsingh, HA; Venkatraman, MS	1
Acton, JJ; Akiyama, TE; Berger, JP; Chang, CH; Colwell, L; Debenham, S; Doebber, T; Einstein, M; Liu, K; McCann, ME; Meinke, PT; Moller, DE; Muise, ES; Tan, Y; Thompson, JR; Wong, KK; Wood, HB; Wu, M; Xu, L	1
Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB	1
Bhattarai, BR; Cho, H; Ham, SW; Han, IO; Hwang, JS; Kafle, B; Kang, JS; Khadka, D; Lee, SM; Park, H	1
Barnes, KF; Carroll, RT; Funk, MO; Geldenhuys, WJ	1
Araki, K; Arita, T; Furukawa, A; Hayashi, S; Kuroha, M; Matsui, Y; Ohsumi, J; Satoh, S; Wakabayashi, K	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Carroll, RT; Darvesh, AS; Funk, MO; Geldenhuys, WJ; Van der Schyf, CJ	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Choi, J; Lee, HS; Park, Y; Yang, Y; Yoon, S	1
Agarwal, AK; Bahnasi, Y; Beech, DJ; Majeed, Y; Milligan, CJ; Naylor, J; Seymour, VA; Sukumar, P; Wilson, LA	1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A	1
Greiner, C; Hieke, M; Ness, J; Schubert-Zsilavecz, M; Steri, R; Weggen, S; Werz, O; Zettl, H	1
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S	1
Aldeco, M; Binda, C; Edmondson, DE; Geldenhuys, WJ; Mattevi, A; Tortorici, M	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Chang, FR; Chuang, DW; El-Shazly, M; Hsieh, CT; Hsieh, TJ; Tsai, YH; Wu, SF; Wu, YC; Yen, CT	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
El-Mansy, MF; Greene, AS; Hoffmann, BR; Sem, DS	1
Dalvie, D; Loi, CM; Smith, DA	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y	1
Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, KK; Yar, MS	1
Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, KK; Shafi, S; Yar, MS	1
Darwish, KM; Hammad, MA; Helal, MA	1
Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G	1
Dhangar, K; Jagtap, R; Karpoormath, R; Noolvi, M; Patel, H; Rane, RA; Shaikh, MS; Sonawane, Y; Surana, S; Thapliyal, N	1
Bahia, MS; Chadha, N; Kaur, M; Silakari, O	1
Angioni, C; Blöcher, R; Boß, M; Brüggerhoff, A; Brüne, B; Diehl, O; Geisslinger, G; Göbel, T; Grundmann, M; Hartmann, M; Heering, J; Kahnt, AS; Kaiser, A; Kostenis, E; Lamers, C; Merk, D; Proschak, E; Schader, T; Schubert-Zsilavecz, M; Steinhilber, D; Weizel, L; Wittmann, SK; Wurglics, M	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Kanojiya, S; Maurya, R; Mishra, A; Pandey, J; Patel, OP; Raju, KS; Saini, D; Shukla, SK; Srivastava, AK; Srivastava, MN; Tamrakar, AK; Taneja, I; Wahajuddin, M; Yadav, PP	1
Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM	1
Hashimoto, Y; Ishikawa, M; Makishima, M; Nomura, S; Toyota, Y	1
Binduga, UE; Gmiński, J; Kaminskyy, DV; Kryshchyshyn, AP; Leja, ML; Lesyk, RB; Pinyazhko, OR; Szychowski, KA; Tobiasz, J	1
Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB	1
Chin, J; Choi, H; Choung, W; Hong, E; Jang, SM; Jang, TH; Jung, HJ; Jung, K; Kim, KH; Kim, SH; Kim, WS; Lee, BR; Lee, G; Lim, JS; Myung, J; Nam, EH; Park, M; Yang, D	1
Geldenhuys, WJ; Konkle, ME; Long, TE; Menze, MA; Robart, AR; Skolik, R	1
Ammazzalorso, A; Amoroso, R; Brunetti, L; Bruno, I; Cama, A; Capone, F; Cerchia, C; De Filippis, B; Fantacuzzi, M; Ferrante, C; Florio, R; Giampietro, L; Laghezza, A; Lavecchia, A; Loiodice, F; Maccallini, C; Recinella, L; Tortorella, P; Verginelli, F	1
Narang, RK; Pathania, S; Rawal, RK	1
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y	1
Dowarah, J; Singh, VP	1
Arifi, S; Bischoff, I; Chaikuad, A; Fürst, R; Gellrich, L; Goebel, T; Heering, J; Heitel, P; Kahnt, A; Kilu, W; Knapp, S; Merk, D; Paulke, A; Pogoda, W; Pollinger, J; Proschak, E; Schubert-Zsilavecz, M; Steinhilber, D; Wurglics, M	1
Norman, BH	1
Aamir Javed, M; Ikram, M; Jadoon, R; Mahnashi, MH; Rashid, U; Sadiq, A; Saeed Jan, M; Shahid, M	1
Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L	1
Brun, RP; Chen, J; Evans, RM; Forman, BM; Spiegelman, BM; Tontonoz, P	1
Auwerx, J; Briggs, MR; De Vos, P; Guerre-Millo, M; Hamann, LG; Lefebvre, AM; Miller, SG; Saladin, R; Staels, B; Wong, K	1
Gimble, JM; McAveney, KM; Yu-Lee, L	1
Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K	1
Cummings, R; Elbrecht, A; Hermes, JD; Li, Y; Mitra, S; Moller, DE; Schaeffer, JM; Smith, RG; Wilkinson, HA; Zhou, G	1
Kadowaki, T	1
Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N	1
Henney, JE	1
Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M	1
Kuritzky, L; Quillen, DM; Samraj, GP	1
Nakajima, M; Shimada, N; Suzuki, M; Tane, K; Yamazaki, H; Yokoi, T	1
Shimizu, N	1
Brown, MN	1
King, AB	1
Reddy, SS	1
DeFronzo, RA	1
Krische, D	1
Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K	1
Bailey, CJ; Krentz, AJ; Melander, A	1
Kitahara, M; Naitoh, T; Tsuruzoe, N	1
Füchtenbusch, M; Schatz, H; Standl, E	1
Baum, U	1
Ludvik, B	1
Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM	1
Stiefelhagen, P	1
Filz, HP	1
Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y	1
Chen, L; Cohen, SE; Kahn, CR	1
Blumenthal, RS; Nass, CM	1
Benbow, A; Stewart, M; Yeoman, G	1
Henry, RR; Mudaliar, S	1
Albrektsen, T; Fleckner, J	1
Banerji, MA; Lebovitz, HE	1
Cheatham, WW; Glazer, NB	1
Janka, HU	1
Coxon, P; Downes, CP; Macphee, CH; Pass, I; Patel, L; Smith, SA	1
Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A	1
Gale, EA	1
Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y	1
Blicklé, JF	1
Burge, MR; Colleran, K; Sood, V	1
Csermely, P; Jermendy, G	1
Algenstaedt, P; Hamann, A	1
Jazet, IM; Meinders, AE	1
Birkeland, KI	1
Pospísilová, Y	1
Quesada-Gómez, JM; Serrano-Alferez, I	1
Scheen, AJ	2
Hsueh, WA; Law, RE	1
Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T	1
Wooltorton, E	1
Lotz, N	1
Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H	1
Khan, MA; St Peter, JV; Xue, JL	1
Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J	1
Boyle, PJ; King, AB; Lau, H; Magar, R; Marchetti, A; Martin, J; Olansky, L	1
Greenberg, AS; Pittas, AG	1
Amiri, F; Cohn, JS; Diep, QN; El Mabrouk, M; Endemann, D; Neves, MF; Schiffrin, EL; Virdis, A	1
O'Moore-Sullivan, TM; Prins, JB	1
Casini, A; Ceni, E; Crabb, DW; Galli, A; Mello, T; Ridolfi, F; Salzano, R; Surrenti, C; Svegliati-Baroni, G; Trozzi, L	1
Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS	1
Braddon, J; Phillips, P	1
Häring, HU; Stumvoll, M	1
Yamanouchi, T	1
Bradley, C	1
Göke, B; Parhofer, KG	1
LaCivita, KA; Villarreal, G	1
Aburatani, H; Blumberg, RS; Kadowaki, T; Matsuhashi, N; Nagai, R; Nakajima, A; Saubermann, LJ; Terauchi, Y; Wada, K; Zhao, S	1
Dey, CS; Kumar, N	1
Kaplowitz, N; Lewis, JH; Watkins, PB	1
Fujisawa, N; Ishimine, S; Kadowaki, T; Kawamori, T; Matsuhashi, N; Nakagama, H; Nakajima, A; Ochiai, M; Osawa, E; Sekihara, H; Wada, K	1
Apolito, RA	1
Antoine, B; Beale, EG; Chauvet, G; Forest, C; Quette, J; Tordjman, J	1
Fischer, S; Hanefeld, M	1
Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM	1
Moses, R	1
Bruemmer, D; de Dios, ST; Dilley, RJ; Ivey, ME; Jennings, GL; Law, RE; Little, PJ	1
Elstner, E; Fenner, MH; Liu, H; Possinger, K; Zang, C	1
Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL	1
Diamant, M; Heine, RJ	1
Chandramouli, J; Tolman, KG	1
Allcock, NM; Manley, HJ	1
de Koning, EJ; Martens, EP; Rabelink, TJ; van Wijk, JP	1
Flight, IH; Lord, JM; Norman, RJ	1
Game, BA; Huang, Y; Lopes-Virella, MF; Xu, M	1
Buse, JB	2
Bach, H; Grüb, M; Hetzel, M; Hombach, V; Marx, N; Walcher, D	1
Papoushek, C	1
Chilton, RJ; Stolar, MW	1
Henry, RR	1
Lau, H; Marchetti, A; Olansky, L	1
Evans, M; Rees, A; Roberts, AW; Thomas, A	1
Narce, M; Poisson, JP	1
Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE	1
Burton, B	1
Asnani, S; DeSouza, C; Fonseca, V; Gilling, L; Suwattee, P	1
Avery, MA; Benson, SC; Bhagavathula, N; Chittiboyina, A; Ellis, CN; Ho, CI; Kurtz, TW; Lal, A; Nerusu, KC; Pershadsingh, HA; Varani, J	1
Haslbeck, M; Jakob, S; Kellerer, M; Linn, T	1
Boyle, PJ; Buse, JB; Kendall, DM; Lau, H; Marchetti, A; Peters Harmel, AL	1
Beverley, C; Chilcott, J; Cowan, J; Czoski-Murray, C; Psyllaki, MA; Warren, E	1
Bode, C; Ernst, S; Leugers, A; Lohrmann, J; Nordt, TK; Sobel, BE; Zirlik, A	1
Althaym, A; Brunmair, B; Clara, R; Fürnsinn, C; Gnaiger, E; Gras, F; Nohl, H; Roden, M; Scharf, N; Staniek, K; Waldhäusl, W	1
Kipnes, MS; Lewin, AJ; Maccubbin, DL; Meneghini, LF; Mitchel, YB; Perevozskaya, IT; Plotkin, DJ; Shah, S; Tobert, JA	1
Cai, ZF; Guo, ZR	1
Alsheikh-Ali, AA; Karas, RH	1
Durbin, RJ	1
Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD	1
Monnier, L; Sauvanet, JP	1
Goto, J; Hiratsuka, M; Hishinuma, T; Mizugaki, M; Suzuki, N; Tayama, R; Tsukamoto, H; Yoshihisa, T	1
Naito, Y; Yoshikawa, T	1
Artwohl, M; Brunmair, B; Fürnsinn, C; Gras, F; Wagner, L; Waldhäusl, W; Zierhut, B	1
Hirakata, M; Imura, Y; Sugiyama, Y; Tozawa, R	1
Basta, G; de Caterina, R; Friedl, R; Hombach, V; Ivanova, N; Jung, A; Marx, N; Rautzenberg, K; Walcher, D; Wautier, MP; Wautiers, JL	1
Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E	1
Jamali, B; Sørensen, LL; Theill, GC	1
Chiquette, E; Defronzo, R; Ramirez, G	1
Bängeroth, K; Elstner, E; Eucker, J; Heider, U; Jakob, C; Krebbel, H; Possinger, K; Sezer, O; Zang, C; Zavrski, I	1
Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM	1
Colman, PG; Hussein, Z; Nankervis, AJ; Proietto, J; Wentworth, JM	1
Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T	1
Camacho, IE; De Strooper, B; Dominguez, D; Merchiers, P; Serneels, L; Spittaels, K	1
Ceni, E; Ferruzzi, P; Fiorelli, G; Galli, A; Grappone, C; Mannelli, M; Milani, S; Serio, M; Tarocchi, M	1
Hanefeld, M	2
Iyer, S; Perez, A; Rajagopalan, R	1
Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM; Zhu, JY	1
Chai, OH; Hwang, PH; Kim, JS; Lee, KS; Lee, MK; Lee, YC; Park, SJ; Song, CH; Yi, HK	1
Brougham, L; Chan, K; Duczak, N; Elliot, M; Lim, HK; Patel, K	1
Artwohl, M; Baumgartner-Parzer, SM; Freudenthaler, A; Fürnsinn, C; Hölzenbein, T; Huttary, N; Waldhäusl, WK	1
Campbell, IW	1
Schumm-Draeger, PM	1
Ahn, JB; Ahn, SK; Kang, SK; Kim, BY; Lee, HW; Lee, JH; Lee, SJ; Shin, JS; Yoon, SS	1
Fröhlich, E; Machicao, F; Wahl, R	1
Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S	1
Mukhtar, R; Reckless, JP	1
Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Pinaire, JA; Tan, MH; Zagar, AJ	1
Dear, AE; Hu, YS; Liu, HB; Medcalf, RL; Simpson, RW	1
Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G	1
Arnold, N; Cheung, NW; Chipps, DR; McLean, M	1
Cho, L; Lewis, BE; Leya, FS; Steen, LH	1
Hirosumi, J; Ita, M; Kawamura, I; Mabuchi, M; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S; Yamamoto, T	1
Avtanski, D; Chang, P; Holcomb, K; Paliou, M; Park, A; Patel, P; Poretsky, L; Schlosser, J; Seto-Young, D	1
Freston, JW; Schlichting, CL; Slavin, DE	1
Jin, SM; Kim, SR; Lee, KS; Lee, YC; Min, KH; Park, HS; Park, SJ	1
Digman, C; Klein, AK; Pittas, AG	1
Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR	1
D'Amico, E; Perfetti, R	1
Bhansali, A; Modi, P	1
Cheng, J; Deng, T; Li, PP; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF	1
Os, I	1
Aramori, I; Fujimura, T; Hosogai, N; Kimura, C; Konishi, S; Mutoh, S; Oe, T; Sakuma, H	1
Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J	1
Brunzell, JD	1
Aragno, M; Collino, M; Danni, O; Dianzani, C; Fantozzi, R; Gallicchio, M; Mastrocola, R; Rosa, AC; Thiemermann, C	1
Laverty, R; Ledingham, JM	1
Adomaityte, J; Qayyum, R	1
Edwards, KL; Greene, RS; Irons, BK; Mazzolini, TA; Sleeper, RB	1
Friedmann, PS; Krentz, AJ	1
Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P	1
Aramori, I; Fujimura, T; Mutoh, S; Ohkubo-Suzuki, A; Sakuma, H	1
Iyer, S; Kalsekar, I; Kavookjian, J; Mody, R; Rajagopalan, R	1
Ciccarelli, L; Cicero, AF; Dangelo, A; Derosa, G; Ferrari, I; Fogari, R; Gaddi, A; Ghelfi, M; Montagna, L; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, S	1
Balusu, P; Buch, HA; Hoffmann, TK; Parker, DL	1
Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR	1
Aramori, I; Fujimura, T; Kimura, C; Mutoh, S; Oe, T; Sakuma, H; Takata, Y	1
Davidson, MB; Navar, MD; Tran, MT	1
Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ	1
Berhanu, P; Demissie, S; Fleck, PR; Khan, MA; Kipnes, MS; Kupfer, SF; Perez, AT; Spanheimer, RC	1
Parson, H; Ullal, J; Vinik, A	1
Smits, P; Tack, CJ	1
Jin, SM; Kim, SR; Kim, UH; Lee, KS; Lee, MK; Lee, YC; Min, KH; Park, HS; Park, SJ	1
de Morais, SM; Fahmi, OA; Liras, JL; Maurer, TS; Mills, JB; Ripp, SL; Trevena, KA	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA	1
Nilsson, PM; Sarafidis, PA	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA	2
Bakris, GL; Sarafidis, PA	1
Horinaka, M; Kouhara, J; Nakata, S; Sakai, T; Shiraishi, T; Wakada, M; Yoshida, T	1
Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R	1
Johansen, OE; Jørgensen, AP	1
Alvarez-Sanchez, R; Hartung, T; Montavon, F; Pähler, A	1
Bonner, SE; Emery, MN; Galloway, M; Grossman, AB; Korbonits, M; Leontiou, C; Merulli, C; Musat, M; Nanzer, AM; Nikookam, K; Powell, M	1
Elstner, E; Eucker, J; Heider, U; Jakob, C; Kaiser, M; Krebbel, H; Sezer, O; Sterz, J; Zang, C; Zavrski, I	1
Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L	1
Campbell, IW; Mariz, S	1
Berlie, HD; Jaber, LA; Kalus, JS	1
Phatak, HM; Yin, DD	1
Hruz, PW; Rudnick, DA; Shikapwashya, O; Tu, S; Turmelle, YP; Yan, Q	1
Flück, CE; Hofer, G; Kempná, P; Mullis, PE	1
Bottomley, J; Diamantopoulos, A; Mariz, S; O'Bryan-Tear, G; Tilden, DP	1
Iversen, PB; Vondeling, H	1
Allemann, S; Braun, M; Chappuis, B; Christ, ER; Diem, P; James, R; Lumb, PJ; Stettler, C; Wierzbicki, AS	1
Ari, N; Aslamaci, S; Irat, AM; Karasu, C	1
Gaikwad, AB; Ramarao, P; Viswanad, B	1
Avtanski, D; Holcomb, K; Kaplun, J; Parikh, G; Patel, P; Poretsky, L; Rosenwaks, Z; Seto-Young, D; Strizhevsky, M	1
Blay, J; Richard, CL	1
Hirosumi, J; Kawamura, I; Kimura, C; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S	1
Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R	1
Batra, RK; Cui, X; Dubinett, SM; Hazra, S; Sharma, S; Tai, HH	1
Hampton, T	1
Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS	1
Hitch, WJ; Jackson, VL; Scott, MA	1
Littenberg, B; MacLean, CD; Ramos-Nino, ME	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Salvadeo, SA	1
Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ	1
Bussel, II; Felgner, J; Jafari, M; Khodayari, B; Mueller, LD; Rose, MR	1
Kalliokoski, A; Neuvonen, M; Neuvonen, PJ; Niemi, M	1
Giaginis, C; Theocharis, S; Tsantili-Kakoulidou, A	1
Baran, R; Bhattacharya, M; Gerrits, CM; Kupfer, S; Manthena, S; Perez, A	1
Lewis, JD; Strom, BL	1
Colca, JR	1
Ambery, P; Bagust, A; Home, P; Mendes da Costa, S; Taylor, M	1
Llorens, S; Mendizabal, Y; Nava, E	3
Solomon, DH; Winkelmayer, WC	1
Lago, RM; Nesto, RW; Singh, PP	1
Itakura, Y; Nakagawa, T; Noguchi, H; Taiji, M; Tsuchida, A; Yamanaka, M	1
Bjørnsdottir, I; Hansen, SH; Jamali, B; Nordfang, O	1
Nemenoff, RA	1
Chalasani, N; Khashab, M	1
Vergès, B	1
Charbonnel, B	1
Anderson, RT; Arondekar, BV; Balkrishnan, R; Camacho, FT; Horblyuk, R; Shenolikar, RA	2
Koro, C; McAfee, AT; Walker, AM	1
Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D	1
Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M	1
Alter, DA; Gomes, T; Hux, JE; Juurlink, DN; Lévesque, LE; Lipscombe, LL	1
Atkin, SL; Cho, LW	1
Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L	1
Dorais, M; LeLorier, J	1
Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Muresan, M; Netter, P; Sebillaud, S; Weryha, G	1
D'Arrigo, T	1
Berneis, K; Braun, M; Chappuis, B; Christ, ER; Diem, P; Rizzo, M; Stettler, C	1
Doggrell, SA	1
Honisett, SY; Komesaroff, PA; Stojanovska, L	1
Carson, S; Norris, SL; Roberts, C	1
Seidel, D; Strohmeyer, T	1
Erdmann, E; Scherbaum, WA	1
Chicco, A; Greyson, CR; Lu, L; Reiter, MJ; Schwartz, GG; Xu, Y	1
Glueck, C; Goldenberg, N	1
Koro, CE; Landon, J; Walker, AM	1
Baran, I; Cangur, S; Dirican, M; Ersoy, C; Eryilmaz, S; Fazlioglu, M; Gul, CB; Imamoglu, S; Ocak, N; Oz, O; Tuncel, E	1
Chilton, R; Sulistio, MS; Thukral, N; Zion, A	1
Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV	1
Chang, MS; Choi, OK; Kim, SW; Kim, SY; Park, KS; Shin, CS	1
DeFronzo, RA; Miyazaki, Y	1
Gani, OA; Sylte, I	1
Kostenbauder, HB	1
Hoffstad, O; Margolis, DJ; Strom, BL	1
Ajjan, RA; Grant, PJ	1
Kenny, C	1
Beysen, C; Boyle, PJ; Decaris, M; Fong, A; Hellerstein, MK; Murphy, EJ; Nagaraja, H; Riiff, T	1
Lasaridis, AN; Sarafidis, PA; Stafylas, PC	1
Derosa, G; Salvadeo, SA	1
Diamond, GA; Kaul, S	1
Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA	1
Burkart, A; Chouinard, M; Corvera, S; Gealekman, O; Nicoloro, SM; Straubhaar, J	1
Furberg, CD; Singh, S	1
Devchand, PR; Hamdy, O; Horton, ES; Nehra, V; Orasanu, G; Plutzky, J; Ziouzenkova, O	1
Kintscher, U	1
Kumar, H; Mishra, M; Tripathi, K; Vijay, SK	1
Felson, S; Fisher, E; Schwartzbard, A; Zinn, A	1
Antonelli, A; Barani, L; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Giannini, R; Marchetti, I; Materazzi, G; Miccoli, P; Minuto, M	1
Grönberg, G; Hansen, SH; Jurva, U; Madsen, KG; Olsen, J; Skonberg, C	1
Carter, L; Odom, J; Williamson, B	1
Aljada, A; Fu, YY; Mousa, SA; O'Connor, L	1
Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL	2
Bernene, J; Bower, B; Hanks, S; Holford, TR; Kocherla, M; Petit, WA; Ruaño, G; Seip, RL; Wencker, D; Windemuth, A	1
Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC	1
Chalasani, N; Vuppalanchi, R	1
Lipscombe, LL	1
Furberg, CD; Loke, YK; Singh, S	1
Cho, N; Momose, Y	1
Bugaj, V; Cunard, R; Dechenes, G; Hummler, E; Pochynyuk, O; Rieg, T; Rossier, B; Schroth, J; Stockand, J; Vallon, V	1
Contreras, R; Fong, DS	1
Bakris, GL; Kalaitzidis, RG; Sarafidis, PA	1
Abbasi, F; Lima, NK; Reaven, GM	1
Krentz, A	1
Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK	1
Gallen, IW; Lumb, AN	1
Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Frascerra, S; Santini, E	1
Debiais, F	1
Anastasilakis, AD; Goulis, DG; Toulis, KA	1
Deng, R; Kaimal, R; King, R; Song, X; Yan, B	1
Gomes, T; Juurlink, DN; Lipscombe, LL; Mamdani, MM	1
Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L	1
Chawla, S; Chogtu, B; Gupta, U; Singh, NP	1
George, J; Hannah, S; Lang, CC	1
Barnett, AH	1
Collino, M; Fantozzi, R; Lombardi, G; Miglio, G; Rattazzi, L; Rosa, AC	1
Bajwa, PJ; Lee, JW; Lytle, C; Straus, DS	1
Panchapakesan, U; Pollock, C; Saad, S	1
Smahelová, A	1
Chen, KC; Kilgore, MW; Pancani, T; Phelps, JT; Porter, NM; Searcy, JL; Thibault, O	1
Sinclair, A; Viljoen, A	1
Retnakaran, R; Zinman, B	1
Armor, B; Burt, R; Townsend, S	1
Dore, DD; Lapane, KL; Mor, V; Trivedi, AN	1
Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM	1
Hobbs, FD; Taylor, C	1
Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW	1
Alexander, CM; Chapell, R; Gould, AL	1
Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM	1
Chae, HJ; Choe, YH; Kim, SR; Lee, KS; Lee, YC; Min, KH; Moon, H; Park, SJ; Yoo, WH	1
Brackenridge, AL; Hovorka, R; Jackson, N; Jefferson, W; Russell-Jones, D; Shojaee-Moradie, F; Stolinski, M; Umpleby, AM	1
Cobitz, AR; Kolatkar, NS; Koro, CE; Osei, SY; Stender, M	1
Bassett, K; Carleton, B; Carney, G; Dormuth, CR; Wright, JM	1
Austin, PC; Gomes, T; Hux, JE; Juurlink, DN; Lipscombe, LL; Mamdani, MM	1
de Vries, CS; Russell-Jones, DL	1
Fisher, M	1
Ersoy, C; Guclu, M; Gul, CB; Imamoglu, S; Kiyici, S; Oral, AY; Oz Gul, O; Tuncel, E; Ulukaya, E; Yilmaz, Y	1
Hamada, Y	1
Han, J; Koh, GY; Koh, YJ; Lee, IK; Park, BH; Park, JH; Park, JW	1
Karpushev, AV; Levchenko, V; Pavlov, TS; Staruschenko, A; Vandewalle, A	1
Derosa, G; Maffioli, P; Tinelli, C	1
Booth, A; Konstantinidis, A; Lambley, RG; Vahdani, K	1
Yki-Järvinen, H	1
Douglas, IJ; Evans, SJ; Pocock, S; Smeeth, L	1
Mannucci, E; Monami, M	1
Dixit, A; Pandey, P	1
Beiderbeck, AB; Sakaguchi, M	1
Allen, E; Chen, R; Hollander, P; Li, J	1
Clerget-Froidevaux, MS; Decherf, S; Demeneix, B; Elgaaied, AB; Guissouma, H; Kouidhi, S; Seugnet, I	1
Depaoli, AM; Higgins, LS	1
Higuchi, A; Ohashi, K; Ouchi, N; Shibata, R; Sono-Romanelli, S; Walsh, K	1
Lai, CC; Yang, CR	1
Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR	1
Homem-de-Mello, P; Honório, KM; Maltarollo, VG	1
He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH	1
Nicholls, P; Young, IS	1
Getty, J; Hansen, MK; Husband, EM; Inglis, SK; Mansley, MK; Wilson, SM	1
Arnold Chan, K; Koro, C; Landon, J; McAfee, AT; Ziyadeh, N	1
Georgianos, PI; Lasaridis, AN; Sarafidis, PA; Saratzis, AN; Stafylas, PC	1
Hu, Z; Lin, Y; Perez-Polo, JR; Ye, Y; Zhang, C	1
Krumholz, HM	1
Caveda, E; Rodriguez, A; Simó, R	1
Kalliokoski, A; Neuvonen, PJ; Niemi, M	1
Açar, G; Akçakoyun, M; Esen, AM; Esen, O; Kahveci, G; Karaahmet, T; Kargin, R; Kirma, C; Pala, S; Tigen, K	1
Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S	1
Alshekhlee, A; Barnholtz-Sloan, JS; Conway, DS; Grommes, C	1
Chevrot, M; Degrace, P; Demizieux, L; Djaouti, L; Gresti, J; Jourdan, T; Vergès, B	1
Wadman, M	1
Larson, RJ; Sheth, SH	1
Bilik, D; Brown, MB; Crosson, JC; Herman, WH; Hsiao, VC; Karter, AJ; Lasser, NL; Mangione, CM; Marrero, DG; McEwen, LN; Selby, JV; Tseng, CW	1
Juurlink, DN	1
Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C	1
Aubert, RE; Chen, W; Haffner, SM; Herrera, V; Pendergrass, M	1
Asao, K; Bilik, D; Brown, MB; Crosson, JC; Duru, OK; Ferrara, A; Herman, WH; Hsiao, VC; Karter, AJ; Kim, C; Lee, PG; Marrero, DG; McEwen, LN; Pomeroy, NE; Selby, JV; Subramanian, U	1
Almdal, T; Boushel, R; Dela, F; Hansen, CN; Haugaard, SB; Madsbad, S; Ploug, T; Prats, C; Rabøl, R	1
Kean, S	1
Rosen, CJ	1
Blankenship, DA; Gamboa, J; Hilow, E; Karl, M; Landreth, GE; Niemi, JP; Sundararajan, S	1
Gang, GT; Hwang, JH; Kim, YH; Lee, CH; Noh, JR; Yang, KJ; Yang, SJ; Yeom, YI	1
Bohn, RL; Chang, CL; Cziraky, MJ; Sarawate, CA; Wertz, DA; Willey, VJ	1
Lecka-Czernik, B	1
Delalonde-Delaunay, L; Donello, J; Luhrs, K; Maurier-Mahé, F; McLaughlin, A; Pallares, D; Rodrigues, GA; Schweighoffer, F; Shurland, DL; Throo, E	1
Liao, X; Wang, Y; Wong, CW	1
Artunc, F; Desch, M; Friedrich, B; Mayer, S; Schreiber, A; Schubert, T; Todorov, VT	1
Fu, X; Han, Y; He, X; Heng, CK; Huang, C; Li, N; Shi, X; Wu, Y; Zhao, Y	1
Li, XJ; Liu, CQ; Wang, LY; Yan, B; Yang, SY; Yu, YX; Zhang, HJ; Zhang, SH; Zhang, W	1
Akahira, J; Hui, XG; Ito, S; Kudo, M; Matsuda, K; Nakamura, Y; Noguchi, N; Okamoto, H; Rainey, WE; Sasano, H; Satoh, F; Sugawara, A; Uruno, A; Yoshikawa, T	1
Alfaro-Cervello, C; Cortes-Canteli, M; Garcia-Verdugo, JM; Luna-Medina, R; Morales-Garcia, JA; Perez-Castillo, A; Santos, A	1
Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S	1
Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC	1
Lipska, KJ; Ross, JS	1
Araki, T; Avtanski, D; Parikh, G; Poretsky, L; Rosenwaks, Z; Seto-Young, D; Strizhevsky, M; Suwandhi, P	1
Louisa, M; Setiabudy, R; Takeuchi, M	1
Tolman, KG	1
Kwok, CS; Loke, YK; Singh, S	1
Hurren, KM; Jaber, LA; Taylor, TN	1
Feldon, SE; Guo, N; Phipps, RP; Woeller, CF	1
Curtis, B; Hall, GC; McMahon, AD; Smith, HT	1
Heazlewood, VJ	1
Baillot-Rudoni, S; Bouillet, B; Brindisi, MC; Duvillard, L; Petit, JM; Poussier, A; Radu, L; Vergès, B	1
Bieganski, RM; Yarmush, ML	1
Egidi, G; Popert, U	1
Paquot, N; Scheen, AJ	1
Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J	1
Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P	1
Jaggi, AS; Sain, H; Sharma, B; Singh, N	1
Andersen, OS; Greathouse, DV; Hemmings, HC; Herold, KF; Rusinova, R; Sanford, RL	1
Derosa, G	1
Karbowska, J; Kochan, Z	1
Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T	1
Desilets, AR; Miller, BW; Willett, KC	1
Afzal, R; Bosch, J; Dagenais, G; Diaz, R; Gerstein, H; Holman, R; Probstfield, J; Punthakee, Z; Ramachandran, A; Riddle, M; Rydén, LE; Yusuf, S; Zinman, B	1
Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N	1
Amin, F; Idrees, M; Jan, NU; Khan, MI; Khan, RU; Salman, M; ur Rahman, I	1
Akiyama, TE; Berger, JP; Castriota, G; Chang, CH; Chen, Y; Doebber, TW; Einstein, M; Lau, F; Li, Y; Liu, K; Liu, W; McCann, ME; McKeever, B; McNamara, L; Meinke, PT; Mosley, RT; Wang, C; Wood, HB; Wu, M; Zhou, G	1
Bardova, K; Flachs, P; Illig, T; Janovska, P; Jilkova, ZM; Kopecky, J; Kuda, O; Kus, V; Rossmeisl, M; Svobodova, M; Wang-Sattler, R; Yu, Z	1
Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J	1
Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC	1
Panadero, A; Pita, J; Rodríguez, E; Rovira, A; Soriano-Guillén, L	1
Amin, J; Crossno, JT; Joyal, T; Li, H; Nemenoff, RA; Poczobutt, J; Sorenson, AL; Sullivan, T; Weiser-Evans, MC	1
Chang, CC; Chang, FR; Chang, WC; Du, YC; Hsieh, TJ; Liu, CS; Wu, YC	1
Chen, B; Desai, P; Ding, Y; He, B; Moorthy, G; Qiu, J; Shin, JH; Sun, Y; Tang, J; Wang, H; Wild, DJ	1
Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP	1
Borsting, E; Cheng, VP; Cunard, R; Glass, CK; Vallon, V	1
Detaille, D; El-Mir, MY; Rigoulet, M; Rodríguez-Villanueva, G; Sánchez-Martín, C; Sanz, MN; Vial, G	1
Ciudin, A; Hernandez, C; Simó, R	1
Hu, W; Liu, D; Yu, Q; Zhang, J	1
Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E	1
Antonelli, A; Bernini, G; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Gelmini, S; Pupilli, C; Ruffilli, I; Sellari-Franceschini, S	1
Amoruso, A; Balìa, C; Breschi, MC; Brunelleschi, S; Carmazzi, Y; Celi, A; Cordazzo, C; Neri, T; Paggiaro, P; Pedrinelli, R; Petrini, S; Stefanelli, F	1
Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S	1
Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y	1
de Bie, S; Geelhoed-Duijvestijn, PH; Herings, RM; Mol, PG; Romio, SA; Ruiter, R; Straus, SM; Stricker, BH; van Herk-Sukel, MP; Visser, LE	1
Chen, YW; Huang, CL; Huang, NK; Huang, WJ; Kuo, TY; Lin, RJ; Yang, JM; Yang, YC	1
Barbieri, M; D'Amico, M; Di Filippo, C; Di Ronza, C; Duan, SZ; Esposito, A; Ferraraccio, F; Marfella, R; Mortensen, RM; Paolisso, G; Rizzo, MR; Rossi, F	1
Ishii, R; Kaku, K; Kikuchi, M; Momomura, S; Odawara, M	1
Chen, T; Cheng, H; Crawford, BH; Ding, G; Jin, X; Saafir, TB; Wagner, MB; Yuan, Z	1
Chambers, KT; Chen, Z; Colca, JR; Finck, BN; Hall, AM; Kletzien, RF; McDonald, WG; Mitra, MS; Qi, N; Vigueira, PA	1
Donnelly, R; Idris, I; Warren, G	1
Cockerill, GW; Pirianov, G; Torsney, E	1
Bowker, SL; Colmers, IN; Johnson, JA; Majumdar, SR	1
Leal, I; Oteri, A; Romio, SA; Schuemie, M; Sturkenboom, M; Trifirò, G	1
Antonelli, A; Colaci, M; Fallahi, P; Ferrari, SM; Ferri, C; Ruffilli, I; Sebastiani, M	1
Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM	1
Carta, AR; Pisanu, A	1
Bilker, WB; Glanz, K; Haynes, K; Lewis, JD; Mamtani, R; Strom, BL; Vaughn, DJ	1
Chen, SG; Cheng, XY; He, JW; Li, H; Lu, ML; Qu, S; Sheng, CJ; Wang, C; Wang, KS; Yu, YC	1
Du, Q; Fan, B; Wang, YJ; Wu, B; Yang, S; Zhao, YY	1
Colhoun, HM; Donnan, PT; Guthrie, B; Leese, GP; Lindsay, RS; Livingstone, SJ; Looker, HC; McKeigue, P; McKnight, J; Morris, AD; Pearson, DW; Pearson, E; Petrie, JR; Philip, S; Reed, C; Sattar, N; Sullivan, FM; Wild, SH	1
Choi, MG; Jung, JS; Kang, YJ; Kim, CH; Kim, SJ; Kim, SS; Park, SH; Ryu, OH; Sim, YB; Suh, HW	1
Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME	1
Chan, DS; Chan, EC; Chui, WK; Ho, HK; Lee, CY; New, LS; Saha, S; Wong, W; Yap, CW	1
Tannen, R; Wang, X; Weiner, MG; Xie, D; Yu, M	1
Cheng, YC; Chiang, MC; Lin, KH; Yen, CH	1
Bucolo, C; Drago, F; Salomone, S; Siarkos, I; Sinagra, T; Tamburella, A; Urso, V	1
Chen, X; Yang, L; Zhai, SD	1
Beydoun, H; Beydoun, M; Kancherla, V; Stadtmauer, L	1
Marks, DH	1
Yin, Q; Zhuang, Y	1
Cho, DH; Han, SH; Jo, I; Kwon, KJ; Lee, EJ; Park, JH; Shin, CY; Song, KH	1
Sullivan, PG; Yonutas, HM	1
Baslé, MF; Chappard, D; Marchand-Libouban, H; Moreau, MF	1
Colao, A; Grasso, LF; Pivonello, R	1
Fox, JC; Lea, S; Metcalfe, H; Plumb, J; Singh, D; Spicer, D; Woodman, P	1
Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW	1
Abdul Jaleel, UC; Balachandran, S; Benjamin, S; Doble, M; Pradeep, S; Sarath Josh, MK; Spener, F; Vijayalekshmi Amma, KS	1
Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D	1
Al Shaar, L; Azar, S; Bashshur, ZF; El-Mollayess, GM; Salti, HI	1
Chen, PC; Chen, RC; Hsu, CY; Lu, CJ; Muo, CH; Sun, Y	1
To, KK; Tomlinson, B	1
Chang, SS; Hu, HY	1
Gomes, T; Hashim, S; Hellings, C; Juurlink, D; Mamdani, M	1
Fang, L; Liu, Y; Mao, G; Tang, H; Wang, N; Yan, X; Zhao, B	1
Chang, CS; Chen, JY; Ho, LC; Maeda, N; Pandya, K; Sung, JM; Tsai, PJ; Tsai, YS	1
Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A	1
Liu, J; Wang, LN	3
Aprahamian, TR; Bonegio, RG; Gharakhanian, R; Rifkin, IR; Weitzner, Z	1
Gong, M; Husain, M; Husain, S; Ibe, B; Li, Y; Morales, E; Paek, D; Rehan, VK; Sakurai, R; Torday, JS	1
Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR	1
Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A	1
Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM	1
Tseng, CH	1
La Caze, A; Niyomnaitham, S; Page, A; Smith, AJ; Whitfield, K	1
Kelder, T; Kleemann, R; Kooistra, T; Radonjic, M; Salic, K; van Ommen, B; Verschuren, L; Wielinga, PY	1
Antonelli, A; Di Domenicantonio, A; Fallahi, P; Ferrari, SM; Ferri, C; Manfredi, A	1
Åberg, F; Arola, J; Boyd, S; Isoniemi, H; Koljonen, V; Nikkilä, K	1
Blanchard, J; Gong, CX; Iqbal, K; Li, X; Li, Y; Liu, F; Yu, Y	1
Bouillet, B; Brindisi, MC; Duvillard, L; Monier, S; Perségol, L; Petit, JM; Vergès, B	1
Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S	1
Chan, EC; Chang, KL; Dawe, GS; Ho, PC; Holmes, E; Nicholson, JK; Pee, HN; Tan, WP	1
Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y	1
Herrigel, DJ; Moss, RA	1
Neuhaus, W; Thal, SC	1
Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z	1
Jia, JP; Liu, J; Wang, LN	1
Abete, P; Bellia, A; Cacciatore, F; Capuani, B; Dave, KR; De Marchis, ML; Della-Morte, D; Donadel, G; Dong, C; Ferroni, P; Fogliame, G; Guadagni, F; Lauro, D; Pacifici, F; Palmirotta, R; Pastore, D; Pileggi, A; Rehni, AK; Ricordi, C; Roselli, M; Rundek, T; Sbraccia, P	1
Bizou, M; Carpéné, C; Grès, S; Hasnaoui, M; Tréguer, K	1
Dangi-Garimella, S	1
Ding, RG; Fan, X; Hu, D; Li, ZJ; Liu, Y; Wang, QJ; Wu, CQ	1
Adams, SH; Akiyama, T; Carstens, E; Dunn, TN; Kim, JB; Knotts, TA; Lee, HW; Sears, DD; Smith, SR	1
Geng, B; He, J; Jiang, H; Kuang, J; Liu, Q; Mo, L; Xu, C; Xu, G	1
Ramesh, T; Rao, PN; Rao, RN	1
Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, K; Shahar Yar, M	1
Li, M; Li, R; Li, Y; Liang, X; Shen, Y; Su, D; Xu, W	1
Doblhammer, G; Fink, A; Heneka, MT	1
Hsu, JC; Lu, CY; Ross-Degnan, D; Wagner, AK; Zhang, F	1
Cheng, H; Jiang, L; Shang, Y; Shi, TL; Wang, L	1
Peuler, JD; Phelps, LE	1
Goto, T; Kato, H; Maruta, K; Nagamine, J; Nagata, R; Nakayama, R; Takata, M; Takazawa, T; Tsuchida, A; Watanabe, K; Yamanaka, M	1
Ichiki, T; Ikeda, J; Kitamoto, S; Kojima, H; Sankoda, C; Sunagawa, K; Takahara, Y; Tokunou, T	1
Chai, Yf; Chwee, Ts; Li, H; Lu, F; Wu, L; Yuan, Yf; Zhu, Qx	1
Awad, KS; Cai, R; Danner, RL; Dougherty, EJ; Elinoff, JM; Ferreyra, GA; Ptasinska, A; Sun, J; Wang, JY; Wang, S	1
Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S	1
Chan, EW; Choi, NK; Griffiths, J; Kimura, M; Kimura, T; Kubota, K; Lai, EC; Man, KK; Nguyen, TA; Ooba, N; Park, BJ; Pratt, NL; Roughead, EE; Sato, T; Shin, JY; Wang, T; Wong, IC; Yang, YH	1
Ambrosius, WT; Banerji, MA; Bauer, DC; Bonds, DE; Chen, H; Cohen, RM; Hamilton, BP; Isakova, T; Josse, RG; Margolis, KL; Schnall, AM; Schwartz, AV; Sellmeyer, DE; Shibli-Rahhal, A; Simmons, DL; Sood, A; Vittinghoff, E; Williamson, JD	1
Alves, C; Batel-Marques, F; Mendes, D	1
Chen, F; Hong, H; Hu, M; Liao, JM; Long, Y; Miao, MX; Sun, HB; Tang, SS; Wang, H; Zhong, KL	1
Li, D; Liu, K; Wang, T; Xu, R; Zhao, D; Zhu, Z	1
Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Peng, X; Steele, VE	1
Chang, KH; Huh, HJ; Lee, K; Lee, MY; Liu, Y; Park, JM	1
Prostran, M; Radenković, M; Stojanović, M	1
Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C	1
Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM	1
Elstner, E; Khoo, BY; Miswan, N; Nadarajan, K; Possinger, K; Shim, SY; Zang, CB	1
Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH	1
Carr, F; Dawed, AY; Donnelly, L; Leese, G; Palmer, CN; Pearson, ER; Tavendale, R; Zhou, K	1
Chen, YT; Liu, YM; Ou, HT; Wu, JS	1
Sharma, SK; Verma, SH	1
Borch-Johnsen, K; Fischer, KE; Hostenkamp, G	1
Colle, R; Corruble, E; de Larminat, D; Fève, B; Hardy, P; Hozer, F; Rotenberg, S; Verstuyft, C	1
Darrah, L; Ondrey, FG; Wudel, J; Wuertz, BR	1
Chothe, PP; Hariparsad, N; Laitinen, L; Moore, A; Sager, JE; Sun, Y; Tsao, H	1
Allen, KM; Coughlan, KA; Mahmood, FN; Ruderman, NB; Saha, AK; Valentine, RJ	1
Azhar, S; Bittner, S; Han, L; Kraemer, FB; Shen, WJ	1
Colca, JR; Cole, SL; Finck, BN; Hodges, WT; Kletzien, RF; McCommis, KS; McDonald, WG; Oonthonpan, L; Schweitzer, GG; Taylor, EB; Vigueira, PA	1
Kang, DR; Kim, DJ; Lee, KJ; Lee, S; Noh, Y; Shin, S	1
Agarwal, J; Cheung, AK; He, Y; Kim, SE; Li, H; Sanders, WG; Terry, CM; Zhuplatov, I	1
Dinney, CP; Ferguson, JE; Kamat, AM; Li, R; McConkey, DJ; Metcalfe, MJ; Mokkapati, S; Navai, N; Nogueras González, GM; Sahai, SK	1
Bendayan, R; Choi, UY; Hoque, MT; Omeragic, A	1
Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z	1
Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR	1
Chen, S; Dai, J; Hua, J; Mao, W; Qiu, Y; Xu, X; Zhou, X; Zhu, M	1
Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E	1
Lee, C; Rehan, VK; Sakurai, R; Shen, H; Walther, FJ; Waring, AJ	1
Adams, C; Agostini, M; Beig, J; Blom, DJ; Chatterjee, K; Fairall, L; Majithia, AR; Marais, AD; Murphy, R; Muskett, FW; Nagy, L; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schoenmakers, E; Schwabe, JWR; Semple, RK; Szatmari, I	1
Kuranaga, T; Ono, Y; Sato, Y; Takatsuki, S; Unno, Y; Wakimoto, T; Yamamoto, H; Yazawa, K	1
Chang, CH; Chen, PC; Chuang, LM; Dong, YH; Ko, WC; Wang, JL; Wu, LC	1
Chen, SH; Liu, XN; Peng, Y; Sun, QY	1
Cole, AL; Dusetzina, SB; Hickson, RP	1
Ponnusamy, K; Singh, SK; Tyagi, RK; Yende, AS	1
Craig, A; Issberner, J; Parvez, F	1
Bendayan, R; Cummins, CL; Kara-Yacoubian, N; Kelschenbach, J; Omeragic, A; Sahin, C; Volsky, DJ	1
Lebovitz, HE	1
Blazina, I; Selph, S	1
Aquilante, CL; Bilker, WB; Bloomgarden, ZT; Brensinger, CM; Dawwas, GK; Deo, R; Dhopeshwarkar, N; Flory, JH; Gagne, JJ; Hennessy, S; Kimmel, SE; Leonard, CE; Soprano, SE	1
Westlund, KN; Zhang, M	1
Aceves, SS; Dohil, L; Dohil, R; Hsieh, L; Kurten, R; Moawad, FJ; Newbury, RO; Nhu, QM	1
Lee, C; Liu, J; Rehan, VK; Sakurai, R; Shin, E; Wang, Y	1
Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A	1
Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH	1
Palka, J; Szoka, L	1
Kaminskyy, D; Khyluk, D; Kryshchyshyn-Dylevych, A; Lesyk, R; Skóra, B; Szychowski, KA	1
Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N	1
Chen, X; Li, H; Li, J; Li, XF; Song, B; Wang, H; Wu, S; Wu, YY; Yang, YL; Yin, SQ	1
Ciaccio, M; Giglio, RV; Ilias, I; Janez, A; Pantea Stoian, A; Papanas, N; Patti, AM; Rizvi, AA; Rizzo, M; Sahebkar, A	1
Jannetto, PJ; Langman, LJ	1

Reviews

156 review(s) available for pioglitazone and rosiglitazone

Article	Year
The PPARs: from orphan receptors to drug discovery. Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4 Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2000
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions. Bioorganic & medicinal chemistry, 2015, Jul-01, Volume: 23, Issue:13 Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antidiuretic Agents; Antineoplastic Agents; Antioxidants; Drug Design; Humans; Molecular Targeted Therapy; Structure-Activity Relationship; Thiazolidinediones	2015
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Role of sulphur-heterocycles in medicinal chemistry: An update. European journal of medicinal chemistry, 2019, Oct-15, Volume: 180 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antihypertensive Agents; Antineoplastic Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Sulfur	2019
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10 Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary	2020
Anti-diabetic drugs recent approaches and advancements. Bioorganic & medicinal chemistry, 2020, 03-01, Volume: 28, Issue:5 Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Molecular Structure; Structure-Activity Relationship	2020
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20 Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution	2020
[Insulin-sensitizing agents]. Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:3 Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	1999
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. La Revue de medecine interne, 1999, Volume: 20 Suppl 3 Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	1999
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones. Hospital practice (1995), 2000, Jan-15, Volume: 35, Issue:1 Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone	2000
[Proper usage of thiazolidinediones]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus. Medicine and health, Rhode Island, 2000, Volume: 83, Issue:4 Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone	2000
The glitazones: proceed with caution. The Western journal of medicine, 2000, Volume: 173, Issue:1 Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain	2000
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2000, Volume: 108, Issue:3 Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annual review of medicine, 2001, Volume: 52 Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone	2001
Insulin resistance and its treatment by thiazolidinediones. Recent progress in hormone research, 2001, Volume: 56 Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[Glitazones. Profile of a new class of substances]. Der Internist, 2001, Volume: 42, Issue:4 Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States	2001
Lessons from the glitazones: a story of drug development. Lancet (London, England), 2001, Jun-09, Volume: 357, Issue:9271 Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States	2001
[Thiazolidinediones: clinical data and perspectives]. Diabetes & metabolism, 2001, Volume: 27, Issue:2 Pt 2 Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2001
Thiazolidinediones: a comparative review of approved uses. Diabetes technology & therapeutics, 2000,Autumn, Volume: 2, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gene Expression Regulation; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration	2000
[Thiazolidinediones--a new class of oral antidiabetic drugs]. Orvosi hetilap, 2001, Jul-22, Volume: 142, Issue:29 Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[Glitazone--a new class of drugs for the treatment of type 2 diabetes]. Deutsche medizinische Wochenschrift (1946), 2001, Aug-24, Volume: 126, Issue:34-35 Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2001
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents]. Nederlands tijdschrift voor geneeskunde, 2001, Aug-11, Volume: 145, Issue:32 Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
Pioglitazone and rosiglitazone for diabetes. Drug and therapeutics bulletin, 2001, Volume: 39, Issue:9 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
[News in oral antidiabetic therapy]. Vnitrni lekarstvi, 2001, Volume: 47, Issue:9 Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Hepatotoxicity with thiazolidinediones: is it a class effect? Drug safety, 2001, Volume: 24, Issue:12 Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone	2001
PPARgamma and atherosclerosis: effects on cell growth and movement. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:12 Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2001
Thiazolidinediones in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:5 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Thiazolidinediones and type 2 diabetes: new drugs for an old disease. The Medical journal of Australia, 2002, Apr-15, Volume: 176, Issue:8 Topics: Adult; Aged; Australia; Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Oral hypoglycaemics. When not to use what. Australian family physician, 2002, Volume: 31, Issue:7 Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Glitazones: clinical effects and molecular mechanisms. Annals of medicine, 2002, Volume: 34, Issue:3 Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
[Insulin sensitizer drugs--review]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2002
The glitazones: a new treatment for type 2 diabetes mellitus. Intensive & critical care nursing, 2002, Volume: 18, Issue:3 Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom	2002
Repaglinide in combination therapy. Diabetes, nutrition & metabolism, 2002, Volume: 15, Issue:6 Suppl Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone	2002
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgraduate medicine, 2003, Volume: Spec No Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, Volume: 63, Issue:13 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Hepatotoxicity of the thiazolidinediones. Clinics in liver disease, 2003, Volume: 7, Issue:2 Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration	2003
Thiazolidinediones and blood lipids in type 2 diabetes. Arteriosclerosis, thrombosis, and vascular biology, 2003, Oct-01, Volume: 23, Issue:10 Topics: Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linear Models; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides	2003
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane database of systematic reviews, 2003, Issue:3 Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2003
The "glitazones": rosiglitazone and pioglitazone. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003, Volume: 25, Issue:10 Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Female; Heart Failure; Humans; Hypoglycemic Agents; Lactation; Pioglitazone; Pregnancy; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain	2003
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clinical therapeutics, 2003, Volume: 25 Suppl B Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2003
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clinical therapeutics, 2003, Volume: 25 Suppl B Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2003
Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clinical therapeutics, 2003, Volume: 25 Suppl B Topics: Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides	2003
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones	2003
Effects of the thiazolidinediones on cardiovascular risk factors. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2002, Volume: 2, Issue:3 Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone	2002
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy]. MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52 Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors	2003
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Health Services Research; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosiglitazone; State Medicine; Thiazolidinediones; Treatment Outcome; United Kingdom	2004
[Peroxisome poliferator-activated receptors and their modulators]. Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:2 Topics: Animals; Humans; Oxazines; Phenylpropionates; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2004
[Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data]. Annales d'endocrinologie, 2004, Volume: 65, Issue:2 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones	2004
Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Chromans; Humans; Ligands; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone	2004
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Archives of internal medicine, 2004, Oct-25, Volume: 164, Issue:19 Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2004
[Glucose-independent impact of the glitazones on the cardiovascular outcome]. MMW Fortschritte der Medizin, 2005, Jan-13, Volume: 147, Issue:1-2 Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Middle Aged; Obesity; Pioglitazone; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2005
The Clinical Significance of PPAR Gamma Agonism. Current molecular medicine, 2005, Volume: 5, Issue:3 Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Models, Chemical; Obesity; Phenotype; Pioglitazone; PPAR gamma; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides	2005
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors	2005
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 3 Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hyperlipidemias; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones	2005
Rational drug design and PPAR agonists. Current diabetes reports, 2005, Volume: 5, Issue:5 Topics: Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
A meta-analysis of the effect of thiazolidinediones on blood pressure. Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:1 Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones	2006
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy, 2006, Volume: 26, Issue:2 Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
The role of PPARs in the microvascular dysfunction in diabetes. Vascular pharmacology, 2006, Volume: 45, Issue:1 Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Microcirculation; Nitric Oxide; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Skin; Thiazolidinediones; Vasculitis	2006
Thiazolidinedione derivatives in type 2 diabetes mellitus. The Netherlands journal of medicine, 2006, Volume: 64, Issue:6 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2006
The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood pressure, 2006, Volume: 15, Issue:3 Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone	2006
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone	2006
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:4 Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2006
Beta-cell preservation with thiazolidinediones. Diabetes research and clinical practice, 2007, Volume: 76, Issue:2 Topics: Chromans; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone	2007
Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes research and clinical practice, 2007, Volume: 76, Issue:2 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials. Current medical research and opinion, 2006, Volume: 22, Issue:11 Topics: Diabetes Mellitus; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Time Factors	2006
Pharmacokinetic interactions with thiazolidinediones. Clinical pharmacokinetics, 2007, Volume: 46, Issue:1 Topics: Diabetes Mellitus; Drug Interactions; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Future directions for insulin sensitizers in disease prevention. Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Mice; Mice, Knockout; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (London, England), 2007, Sep-29, Volume: 370, Issue:9593 Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:11 Topics: Animals; Antineoplastic Agents; Humans; Lung Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2007
Use of insulin sensitizers in NASH. Endocrinology and metabolism clinics of North America, 2007, Volume: 36, Issue:4 Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone	2007
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels. Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials. Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
[Therapy with glitazones--a risk for cardiovascular disease?]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49 Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Cardiovascular risk in women with polycystic ovary syndrome. Minerva endocrinologica, 2007, Volume: 32, Issue:4 Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss	2007
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:3 Topics: Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
The anti-atherogenic effects of thiazolidinediones. Current diabetes reviews, 2007, Volume: 3, Issue:1 Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones	2007
Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Current diabetes reviews, 2007, Volume: 3, Issue:2 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Prediabetic State; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva ginecologica, 2008, Volume: 60, Issue:1 Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infant, Newborn; Lactation; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2008
PPARgamma agonists and coronary atherosclerosis. Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides	2008
Pleiotropic effects of thiazolidinediones. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:7 Topics: Atherosclerosis; Body Fat Distribution; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
The cardiovascular safety of rosiglitazone. Expert opinion on drug safety, 2008, Volume: 7, Issue:4 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Rosiglitazone and the thiazolidinediones: a changing context. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. International journal of cardiology, 2009, Jan-24, Volume: 131, Issue:3 Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Edema; Heart Failure; Humans; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Secondary Prevention; Thiazolidinediones	2009
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Current clinical pharmacology, 2008, Volume: 3, Issue:2 Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Rosiglitazone and cardiovascular risk. Current atherosclerosis reports, 2008, Volume: 10, Issue:5 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones	2008
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:13 Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clinical cardiology, 2008, Volume: 31, Issue:9 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1 Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss	2009
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Jan-06, Volume: 180, Issue:1 Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Current topics in medicinal chemistry, 2008, Volume: 8, Issue:17 Topics: Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Ligands; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
Effects of thiazolidinediones beyond glycaemic control. Current pharmaceutical design, 2009, Volume: 15, Issue:5 Topics: Animals; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes/metabolism research and reviews, 2009, Volume: 25, Issue:2 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases	2009
Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology (Carlton, Vic.), 2009, Volume: 14, Issue:3 Topics: Animals; Biological Transport; Body Water; Epithelial Sodium Channels; Humans; Immediate-Early Proteins; Kidney Tubules, Proximal; Pioglitazone; PPAR gamma; Protein Serine-Threonine Kinases; Rosiglitazone; Sodium; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Thiazolidinediones	2009
[Insulin sensitizing drugs]. Vnitrni lekarstvi, 2009, Volume: 55, Issue:4 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2009
Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:8 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipoproteins; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides	2009
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:11 Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2009
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International journal of clinical practice, 2009, Volume: 63, Issue:9 Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance	2009
[Relationship between insulin resistance and bone metabolism]. Clinical calcium, 2009, Volume: 19, Issue:9 Topics: Adipokines; Animals; Bone and Bones; Carbohydrate Metabolism; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Thiazolidinediones and the liver in humans. Current opinion in lipidology, 2009, Volume: 20, Issue:6 Topics: Diabetes Mellitus, Type 2; Fats; Fatty Liver; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? Current diabetes reports, 2009, Volume: 9, Issue:5 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2009
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. The American journal of clinical nutrition, 2010, Volume: 91, Issue:1 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Pioglitazone; PPAR gamma; Quinolines; Retinoid X Receptors; Rosiglitazone; Sulfonamides; Thiazolidinediones	2010
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:5 Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Proteinuria; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2010
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Current drug safety, 2010, Jul-02, Volume: 5, Issue:3 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
SLCO1B1 polymorphism and oral antidiabetic drugs. Basic & clinical pharmacology & toxicology, 2010, Volume: 107, Issue:4 Topics: Administration, Oral; Alleles; Carbamates; Cyclohexanes; Genotype; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Organic Anion Transporters; Phenylalanine; Pioglitazone; Piperidines; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones	2010
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC infectious diseases, 2010, Jun-23, Volume: 10 Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2010
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Current osteoporosis reports, 2010, Volume: 8, Issue:4 Topics: Animals; Bone Density; Cell Differentiation; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Osteoporosis; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2010
The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. Diabetes research and clinical practice, 2010, Volume: 90, Issue:3 Topics: C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clinical endocrinology, 2011, Volume: 74, Issue:3 Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Testosterone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides	2011
A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations. Acta medica Indonesiana, 2011, Volume: 43, Issue:1 Topics: Asian People; Blood Glucose; Body Mass Index; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Pioglitazone; Prevalence; Rosiglitazone; Thiazolidinediones	2011
The safety of thiazolidinediones. Expert opinion on drug safety, 2011, Volume: 10, Issue:3 Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (Clinical research ed.), 2011, Mar-17, Volume: 342 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Prognosis; Publication Bias; Risk Factors; Rosiglitazone; Thiazolidinediones	2011
Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:11 Topics: Alzheimer Disease; Animals; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2011
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:38 Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss	2011
Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Current topics in medicinal chemistry, 2012, Volume: 12, Issue:6 Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Humans; Ligands; Pioglitazone; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2012
Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection? Current vascular pharmacology, 2013, Volume: 11, Issue:3 Topics: Animals; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2013
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Sep-04, Volume: 184, Issue:12 Topics: Adult; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Incidence; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms	2012
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotoxicity research, 2013, Volume: 23, Issue:2 Topics: Animals; Antiparkinson Agents; Encephalitis; Humans; Microglia; Parkinson Disease; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2013
Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Advances in therapy, 2012, Volume: 29, Issue:9 Topics: Androgens; Blood Glucose; Body Weight; Female; Humans; Insulin; Insulin Resistance; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2012
Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chinese medical journal, 2012, Volume: 125, Issue:23 Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2012
Drug utilization, safety and clinical use of Actos and Avandia. The International journal of risk & safety in medicine, 2013, Jan-01, Volume: 25, Issue:1 Topics: Alabama; Cost-Benefit Analysis; Drug Substitution; Drug Utilization Review; Health Care Costs; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2013
Targeting PPAR isoforms following CNS injury. Current drug targets, 2013, Volume: 14, Issue:7 Topics: Animals; Brain Injuries; Drug Design; Humans; Mitochondrial Proteins; Molecular Targeted Therapy; Neuroprotective Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Protein Isoforms; Rosiglitazone; Spinal Cord Injuries; Thiazolidinediones	2013
Investigational therapies for acromegaly. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:8 Topics: Acromegaly; Dacarbazine; Drugs, Investigational; Human Growth Hormone; Humans; Octreotide; Pioglitazone; Rosiglitazone; Somatostatin; Temozolomide; Thiazolidinediones	2013
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2014, Jan-08, Issue:1 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones	2014
The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes care, 2014, Volume: 37, Issue:3 Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2014
A review on thiazolidinediones and bladder cancer in human studies. Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews, 2014, Volume: 32, Issue:1 Topics: Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms	2014
Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines. Recent patents on inflammation & allergy drug discovery, 2014, Volume: 8, Issue:2 Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Europe; Humans; Immunity, Cellular; Immunomodulation; Inflammation; Patents as Topic; Pioglitazone; PPAR gamma; Receptors, CXCR3; Rosiglitazone; Th1 Cells; Thiazolidinediones	2014
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones	2014
The blood-brain barrier as a target in traumatic brain injury treatment. Archives of medical research, 2014, Volume: 45, Issue:8 Topics: Blood-Brain Barrier; Brain Edema; Brain Injuries; Cell Hypoxia; Humans; Hypoglycemic Agents; Inflammation; Myosin-Light-Chain Kinase; Neurodegenerative Diseases; Neuroprotective Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Glucocorticoid; Rosiglitazone; Thiazolidinediones	2014
Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. Drugs & aging, 2015, Volume: 32, Issue:1 Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2015
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics, 2014, Volume: 15, Issue:16 Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precision Medicine; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone	2014
The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis. The International journal of neuroscience, 2016, Volume: 126, Issue:4 Topics: Alzheimer Disease; Benzimidazoles; Benzoates; Humans; Pioglitazone; PPAR gamma; Rosiglitazone; Telmisartan; Thiazolidinediones	2016
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:5 Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E	2015
Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Male; Patient Selection; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States	2015
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2015, Oct-29, Issue:10 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones	2015
Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials. European journal of clinical pharmacology, 2016, Volume: 72, Issue:4 Topics: Animals; Endothelium, Vascular; Humans; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vasodilation	2016
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC cardiovascular disorders, 2016, Jan-15, Volume: 16 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2016
PPAR-γ Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry, 2017, Volume: 50, Issue:2 Topics: Antidepressive Agents; Biomarkers; Blood Glucose; Depressive Disorder, Major; Fasting; Glucose Tolerance Test; Humans; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2017
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future cardiology, 2017, Volume: 13, Issue:3 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Thiazolidinediones	2017
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety. Burns : journal of the International Society for Burn Injuries, 2018, Volume: 44, Issue:6 Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds	2018
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC pharmacology & toxicology, 2017, 10-23, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin	2017
Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials. Scientific reports, 2017, 10-31, Volume: 7, Issue:1 Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Myocardial Revascularization; Odds Ratio; Percutaneous Coronary Intervention; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome	2017
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane database of systematic reviews, 2017, 11-29, Volume: 11 Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin Resistance; Live Birth; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2017
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2017, 12-02, Volume: 12 Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin	2017
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. Journal of cellular physiology, 2019, Volume: 234, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin	2019
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. Behavioural brain research, 2019, 10-17, Volume: 372 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins	2019
Thiazolidinediones: the Forgotten Diabetes Medications. Current diabetes reports, 2019, 11-27, Volume: 19, Issue:12 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones	2019
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Systematic reviews, 2019, 11-29, Volume: 8, Issue:1 Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone	2019
Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain. Molecules (Basel, Switzerland), 2020, Mar-03, Volume: 25, Issue:5 Topics: Animals; Humans; Hyperalgesia; Mice; Neuralgia; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones	2020
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular metabolism, 2021, Volume: 50 Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E	2021
Effects of antidiabetic drugs on psoriasis: A meta-analysis. European journal of clinical investigation, 2021, Volume: 51, Issue:2 Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatment Outcome	2021
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clinical endocrinology, 2022, Volume: 96, Issue:6 Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone	2022
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas, Lithuania), 2022, Oct-17, Volume: 58, Issue:10 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones	2022

Trials

36 trial(s) available for pioglitazone and rosiglitazone

Article	Year
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes care, 2000, Volume: 23, Issue:4 Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone	2000
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes care, 2002, Volume: 25, Issue:4 Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone	2002
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical therapeutics, 2004, Volume: 26, Issue:3 Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pioglitazone; Rosiglitazone; Simvastatin; Thiazolidinediones	2004
Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2004
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical therapeutics, 2004, Volume: 26, Issue:5 Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2004
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes research and clinical practice, 2005, Volume: 69, Issue:1 Topics: Aged; Blood Pressure; Body Size; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides	2005
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes care, 2005, Volume: 28, Issue:7 Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clinical therapeutics, 2005, Volume: 27, Issue:10 Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors	2005
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:11 Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2005
Peroxisome proliferator-activated receptors increase human sebum production. The Journal of investigative dermatology, 2006, Volume: 126, Issue:9 Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones	2006
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes & vascular disease research, 2006, Volume: 3, Issue:1 Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipid Metabolism; Lipids; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides	2006
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled Clinical therapeutics, 2006, Volume: 28, Issue:5 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocystine; Humans; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2006
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:4 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones	2006
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes/metabolism research and reviews, 2007, Volume: 23, Issue:5 Topics: Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Male; Metformin; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides	2007
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal medicine journal, 2007, Volume: 37, Issue:2 Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertension research : official journal of the Japanese Society of Hypertension, 2007, Volume: 30, Issue:5 Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes care, 2007, Volume: 30, Issue:10 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones	2007
No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British journal of clinical pharmacology, 2008, Volume: 65, Issue:1 Topics: Adult; Cross-Over Studies; Female; Genotype; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pioglitazone; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones	2008
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta diabetologica, 2008, Volume: 45, Issue:1 Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones	2008
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:3 Topics: Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Fasting; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine, 2008, Volume: 33, Issue:1 Topics: Adiponectin; Arteries; Blood Glucose; Body Mass Index; Capillary Resistance; Diabetes Mellitus, Type 2; Elasticity; Female; Glycemic Index; Humans; Hypoglycemic Agents; Leptin; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones	2008
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. Journal of the American College of Cardiology, 2008, Sep-02, Volume: 52, Issue:10 Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelins; Female; Humans; Hypoglycemic Agents; In Vitro Techniques; Inflammation; Male; Mice; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1	2008
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta diabetologica, 2009, Volume: 46, Issue:1 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Neovascularization, Pathologic; Patient Selection; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2009
Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. Singapore medical journal, 2009, Volume: 50, Issue:4 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2009
Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:5 Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones	2009
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:1 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Pilot Projects; Pioglitazone; Placebos; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Solubility; Thiazolidinediones	2010
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12 Topics: Adamantane; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Pioglitazone; Rosiglitazone; Thiazolidinediones; Young Adult	2009
Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. Echocardiography (Mount Kisco, N.Y.), 2010, Volume: 27, Issue:5 Topics: Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Systole; Thiazolidinediones	2010
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes & vascular disease research, 2011, Volume: 8, Issue:2 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States	2011
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia, 2012, Volume: 55, Issue:1 Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Neoplasms; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2012
A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes. Diabetes & vascular disease research, 2012, Volume: 9, Issue:3 Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; N-Acetylneuraminic Acid; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2012
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes/metabolism research and reviews, 2012, Volume: 28, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2012
Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study. Current medical research and opinion, 2012, Volume: 28, Issue:6 Topics: Adult; Age of Onset; Aged; Algorithms; Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome	2012
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clinical therapeutics, 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms	2012
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10 Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Rabbits; Rosiglitazone; Thiazolidinediones; Vasodilation	2014
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:11 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Longitudinal Studies; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones	2015

Other Studies

426 other study(ies) available for pioglitazone and rosiglitazone

Article	Year
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. Journal of medicinal chemistry, 1994, Nov-11, Volume: 37, Issue:23 Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles	1994
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3 Topics: Animals; Cell Line; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Thiazoles; Transcription Factors	1996
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 284, Issue:2 Topics: 3T3 Cells; Adipocytes; Animals; Benzoxazoles; Female; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Phenylpropionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors	1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. Journal of medicinal chemistry, 1998, Dec-03, Volume: 41, Issue:25 Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine	1998
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists. Bioorganic & medicinal chemistry letters, 1999, Dec-06, Volume: 9, Issue:23 Topics: Animals; Biological Availability; Humans; Indoles; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors	1999
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorganic & medicinal chemistry letters, 2001, Dec-17, Volume: 11, Issue:24 Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine	2001
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. Journal of medicinal chemistry, 2002, Feb-14, Volume: 45, Issue:4 Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides	2002
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. Journal of medicinal chemistry, 2003, Apr-10, Volume: 46, Issue:8 Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors	2003
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. Journal of medicinal chemistry, 2003, Nov-06, Volume: 46, Issue:23 Topics: Alkenes; Amino Acid Sequence; Animals; Binding Sites; Biological Availability; Cell Line; Crystallography, X-Ray; Dimerization; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Sequence Data; Propionates; Rats; Receptors, Cytoplasmic and Nuclear; Sequence Alignment; Stereoisomerism; Transcription Factors; Transcriptional Activation	2003
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:3 Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular; DNA, Complementary; Estrone; Hepatocytes; Humans; Hypoglycemic Agents; Molecular Sequence Data; Oocytes; Organic Anion Transporters; Pioglitazone; Protein Binding; Quinones; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Troglitazone	2004
Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2. Bioorganic & medicinal chemistry letters, 2005, Mar-15, Volume: 15, Issue:6 Topics: Adipocytes; Animals; Cells, Cultured; Drug Design; Ligands; Models, Molecular; Molecular Structure; PPAR gamma; Prostaglandin D2; Protein Binding; Rats; Rosiglitazone; Thiazolidinediones	2005
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. Journal of medicinal chemistry, 2006, Jul-13, Volume: 49, Issue:14 Topics: Adipocytes; Adipogenesis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug Design; Humans; Hypolipidemic Agents; Insulin Resistance; Interleukins; Keratinocytes; Models, Molecular; Molecular Structure; Phenylacetates; PPAR gamma; Rats; Rats, Zucker; Structure-Activity Relationship; Thiazolidinediones; Thioctic Acid	2006
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w Journal of medicinal chemistry, 2009, Jul-09, Volume: 52, Issue:13 Topics: Animals; Blood Volume; Body Fluids; Diabetes Mellitus, Type 2; Dogs; Haplorhini; Humans; Hypoglycemic Agents; Indoles; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2009
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14 Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship	2009
Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects. Bioorganic & medicinal chemistry letters, 2009, Nov-01, Volume: 19, Issue:21 Topics: Animals; Anti-Obesity Agents; Binding Sites; Blood Glucose; Catalytic Domain; Computer Simulation; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Phenyl Ethers; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazolidinediones	2009
Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET. Bioorganic & medicinal chemistry letters, 2010, Feb-01, Volume: 20, Issue:3 Topics: Animals; Binding Sites; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Design; Mitochondria, Liver; Mitochondrial Proteins; Protein Structure, Secondary; Rats; Structure-Activity Relationship; Thiazolidinediones	2010
Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives. Bioorganic & medicinal chemistry letters, 2010, Apr-01, Volume: 20, Issue:7 Topics: Animals; Benzofurans; Crystallography, X-Ray; Diabetes Mellitus; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Models, Molecular; PPAR gamma	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorganic & medicinal chemistry letters, 2010, Sep-01, Volume: 20, Issue:17 Topics: Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists. Bioorganic & medicinal chemistry, 2010, Dec-01, Volume: 18, Issue:23 Topics: Binding Sites; Computer Simulation; HEK293 Cells; Humans; PPAR gamma; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship	2010
Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Molecular pharmacology, 2011, Volume: 79, Issue:6 Topics: Calcium; Cell Line; Humans; Patch-Clamp Techniques; Rosiglitazone; Thiazolidinediones; TRPC Cation Channels; TRPM Cation Channels	2011
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7 Topics: Glutathione; Pharmacology; Sulfur Radioisotopes	2011
SAR studies of acidic dual γ-secretase/PPARγ modulators. Bioorganic & medicinal chemistry, 2011, Sep-15, Volume: 19, Issue:18 Topics: Amyloid Precursor Protein Secretases; Animals; Caproates; Cell Survival; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Conformation; PPAR gamma; Recombinant Proteins; Sheep; Stereoisomerism; Structure-Activity Relationship	2011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors	2012
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS medicinal chemistry letters, 2011, Oct-15, Volume: 3, Issue:1 Topics:	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Synthesis of chalcone derivatives as potential anti-diabetic agents. Bioorganic & medicinal chemistry letters, 2012, Jun-15, Volume: 22, Issue:12 Topics: 3T3-L1 Cells; Adipocytes; Animals; Biological Transport, Active; Chalcones; Diabetes Mellitus; Glucose; Humans; Hypoglycemic Agents; Mice; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. Journal of medicinal chemistry, 2012, Oct-11, Volume: 55, Issue:19 Topics: Animals; Chromatography, Affinity; Gluconeogenesis; Glycolysis; Hypoglycemic Agents; Ion Channels; Lipid Metabolism; Mitochondria; Myocardium; Oxidoreductases; Pioglitazone; Protein Binding; Proteome; Proteomics; Rats; Rosiglitazone; Synaptic Transmission; Thiazolidinediones	2012
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index	2014
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression. Bioorganic & medicinal chemistry letters, 2014, Jul-15, Volume: 24, Issue:14 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Liver; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Rats; Rats, Wistar; Risk Assessment; Streptozocin; Thiazolidinediones	2014
Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists. European journal of medicinal chemistry, 2014, Nov-24, Volume: 87 Topics: Animals; Blood Glucose; Computer Simulation; Diabetes Mellitus, Experimental; Drug Design; Female; Gene Expression Regulation; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Liver; Male; Molecular Docking Simulation; Molecular Structure; Oxadiazoles; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2014
Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation. Bioorganic & medicinal chemistry letters, 2014, Nov-15, Volume: 24, Issue:22 Topics: Binding Sites; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Pioglitazone; PPAR gamma; Protein Structure, Tertiary; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones	2014
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity. Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Humans; Indoleacetic Acids; Mice; Mice, Mutant Strains; Molecular Structure	2015
Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS. Bioorganic & medicinal chemistry letters, 2015, May-01, Volume: 25, Issue:9 Topics: Apoptosis; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Thiazolidinediones	2015
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. Journal of medicinal chemistry, 2016, Jan-14, Volume: 59, Issue:1 Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Hypertension; In Vitro Techniques; Metabolic Syndrome; Mice; Microsomes, Liver; PPAR gamma; Rats; Structure-Activity Relationship	2016
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents. Journal of natural products, 2016, 05-27, Volume: 79, Issue:5 Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Molecular Structure; Murraya; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin	2016
Identification of small molecules that bind to the mitochondrial protein mitoNEET. Bioorganic & medicinal chemistry letters, 2016, 11-01, Volume: 26, Issue:21 Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones	2016
Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression. Bioorganic & medicinal chemistry letters, 2017, 06-15, Volume: 27, Issue:12 Topics: Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2017
Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ). European journal of medicinal chemistry, 2017, Dec-01, Volume: 141 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; PPAR gamma; RNA, Messenger; Structure-Activity Relationship; Thiazolidines	2017
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. Bioorganic & medicinal chemistry, 2018, 12-01, Volume: 26, Issue:22 Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones	2018
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR. Bioorganic & medicinal chemistry letters, 2019, 02-15, Volume: 29, Issue:4 Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mice; Oxadiazoles; PPAR gamma; Proof of Concept Study; Pyrimidines; Pyrimidinones; Structure-Activity Relationship	2019
Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1. Bioorganic & medicinal chemistry letters, 2019, 04-01, Volume: 29, Issue:7 Topics: Hep G2 Cells; Humans; Ligands; Membrane Proteins; Molecular Docking Simulation; Pioglitazone; Protein Binding; Rosiglitazone	2019
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome. ACS medicinal chemistry letters, 2019, Apr-11, Volume: 10, Issue:4 Topics:	2019
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ. Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13 Topics: Amino Acid Sequence; Animals; Drug Evaluation, Preclinical; Male; Mice; Models, Molecular; PPAR gamma; Protein Conformation; Thyroxine	2020
Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors. Bioorganic & medicinal chemistry letters, 2022, 11-15, Volume: 76 Topics: Hydrazones; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Thiazolidines	2022
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. The Journal of biological chemistry, 1995, Nov-24, Volume: 270, Issue:47 Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	1995
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 1995, Dec-01, Volume: 83, Issue:5 Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Carrier Proteins; Cell Differentiation; Complement Factor D; DNA-Binding Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fibroblasts; Hypoglycemic Agents; Ligands; Mice; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Pioglitazone; Prostaglandin D2; Prostaglandins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Serine Endopeptidases; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation	1995
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4 Topics: Adipocytes; Adipose Tissue; Animals; Base Sequence; DNA Primers; Enzyme Activation; Gene Expression; Humans; Leptin; Liver; Molecular Sequence Data; Organ Size; Pioglitazone; Promoter Regions, Genetic; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	1996
Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology, 1996, Volume: 137, Issue:12 Topics: Adipocytes; Animals; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Mice; Pioglitazone; Receptors, Prolactin; Rosiglitazone; Stem Cells; Stromal Cells; Thiazoles; Thiazolidinediones	1996
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships. Chemical & pharmaceutical bulletin, 1997, Volume: 45, Issue:12 Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone	1997
Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Molecular endocrinology (Baltimore, Md.), 1998, Volume: 12, Issue:10 Topics: Animals; Binding Sites; CREB-Binding Protein; Cricetinae; Energy Transfer; Estrogen Receptor alpha; Histone Acetyltransferases; Nuclear Proteins; Nuclear Receptor Coactivator 1; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Rosiglitazone; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors	1998
From the Food and Drug Administration. JAMA, 1999, Sep-08, Volume: 282, Issue:10 Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration	1999
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology, 1999, Volume: 140, Issue:11 Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	1999
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica; the fate of foreign compounds in biological systems, 2000, Volume: 30, Issue:1 Topics: Chromans; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Oxidation-Reduction; Pioglitazone; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Xenobiotics	2000
How should patients taking the discontinued diabetes drug troglitazone be managed? Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:6 Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
Pharmacologic therapy for type 2 diabetes mellitus. Annals of internal medicine, 2000, Jul-04, Volume: 133, Issue:1 Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration	2000
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts. European journal of pharmacology, 2000, Jul-14, Volume: 400, Issue:1 Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E	2000
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ (Clinical research ed.), 2000, Jul-29, Volume: 321, Issue:7256 Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1. Cell biology and toxicology, 2000, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Carcinogens; Cell Survival; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Ligands; Monocytes; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha	2000
[Thiazolidinediones in type 2 diabetes]. Medizinische Monatsschrift fur Pharmazeuten, 2000, Volume: 23, Issue:7 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. MMW Fortschritte der Medizin, 2000, Jul-20, Volume: 142, Issue:28-29 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
Information on thiazolidinediones. Lancet (London, England), 2000, Jul-15, Volume: 356, Issue:9225 Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration	2000
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000]. Der Internist, 2000, Volume: 41, Issue:9 Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
[Insulin sensitizer. A new therapy option for type 2 diabetic patients]. MMW Fortschritte der Medizin, 2000, Sep-21, Volume: 142, Issue:38 Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochemical and biophysical research communications, 2000, Nov-30, Volume: 278, Issue:3 Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured	2000
Unraveling the mechanism of action of thiazolidinediones. The Journal of clinical investigation, 2000, Volume: 106, Issue:11 Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. The American journal of managed care, 2000, Volume: 6, Issue:24 Suppl Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States	2000
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early]. MMW Fortschritte der Medizin, 2000, Nov-23, Volume: 142, Issue:47 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ (Clinical research ed.), 2001, Jan-27, Volume: 322, Issue:7280 Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells. Molecular pharmacology, 2001, Volume: 59, Issue:3 Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation	2001
Anticipated US approval for rosiglitazone and pioglitazone. Diabetes, obesity & metabolism, 1999, Volume: 1, Issue:3 Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration	1999
A comprehensive review of the antidiabetic agent rosiglitazone. Clinical therapeutics, 2001, Volume: 23, Issue:2 Topics: Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	2001
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Current biology : CB, 2001, May-15, Volume: 11, Issue:10 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Genes, Tumor Suppressor; Humans; Phosphoric Monoester Hydrolases; Pioglitazone; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation	2001
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertension research : official journal of the Japanese Society of Hypertension, 2001, Volume: 24, Issue:3 Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone	2001
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. European journal of pharmacology, 2001, Jun-29, Volume: 423, Issue:1 Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2001
[Glitazones--a new therapeutic principle in diabetes]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2001, Sep-20, Volume: 121, Issue:22 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Nonhypoglycemic effects of thiazolidinediones. Annals of internal medicine, 2001, Dec-04, Volume: 135, Issue:11 Topics: Adipocytes; Humans; Hypoglycemic Agents; Osteogenesis; Osteoporosis; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life sciences, 2001, Dec-14, Volume: 70, Issue:4 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured	2001
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jan-22, Volume: 166, Issue:2 Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones]. MMW Fortschritte der Medizin, 2002, Jan-24, Volume: 144, Issue:3-4 Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation, 2002, Mar-12, Volume: 105, Issue:10 Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2002
[Type 2 diabetes. How can the infarction risk be reduced?]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents	2002
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circulation research, 2002, Apr-05, Volume: 90, Issue:6 Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha	2002
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clinical therapeutics, 2002, Volume: 24, Issue:3 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sample Size; Thiazoles; Thiazolidinediones	2002
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation, 2002, May-14, Volume: 105, Issue:19 Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Proteins; Cell Division; Collagen; DNA; Drug Administration Schedule; Endothelium, Vascular; In Vitro Techniques; Inflammation; Injections, Subcutaneous; Lipids; Male; NF-kappa B; Pioglitazone; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents; Vasodilator Agents	2002
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002, Volume: 122, Issue:7 Topics: Animals; Benzhydryl Compounds; Bile Ducts; Carbon Tetrachloride; Cell Division; Cells, Cultured; Collagen; Dimethylnitrosamine; DNA; Epoxy Compounds; Fibronectins; Hypoglycemic Agents; Ligation; Liver; Liver Cirrhosis; Male; Phenols; Pioglitazone; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2002, Volume: 16, Issue:9 Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
[Glinides and glitazones in diabetes treatment. Are they really effective?]. MMW Fortschritte der Medizin, 2002, May-02, Volume: 144, Issue:18 Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome	2002
[Meta-analysis shows: insulin sensitizer is safe for the liver]. MMW Fortschritte der Medizin, 2002, Oct-03, Volume: 144, Issue:40 Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2002
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Current medical research and opinion, 2002, Volume: 18, Issue:6 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides	2002
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflammatory bowel diseases, 2002, Volume: 8, Issue:5 Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th2 Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2002
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochemical pharmacology, 2003, Jan-15, Volume: 65, Issue:2 Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine	2003
Did this drug cause my patient's hepatitis? Annals of internal medicine, 2003, Jan-21, Volume: 138, Issue:2 Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postmarketing; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2003
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 2003, Volume: 124, Issue:2 Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Female; Immunohistochemistry; Ligands; Mice; Mice, Inbred BALB C; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2003
Initial management of glycemia in type 2 diabetes. The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. The Journal of biological chemistry, 2003, May-23, Volume: 278, Issue:21 Topics: Adipocytes; Adrenergic beta-Agonists; Animals; Cells, Cultured; Cyclic AMP; Enzyme Activation; Esterification; Fatty Acids; Female; Gene Expression; Glycerol; Glycerol Kinase; Homeostasis; Hypoglycemic Agents; Isoproterenol; Lipid Metabolism; Lipolysis; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Pyruvic Acid; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Viscera	2003
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors	2003
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. American journal of physiology. Endocrinology and metabolism, 2003, Volume: 285, Issue:2 Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2003
Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation, 2003, May-27, Volume: 107, Issue:20 Topics: Becaplermin; Cell Count; Cell Cycle; Cell Division; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Ligands; Mammary Arteries; Mitogens; Muscle, Smooth, Vascular; Phosphorylation; Pioglitazone; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Radial Artery; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Saphenous Vein; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2003
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast cancer research and treatment, 2003, Volume: 79, Issue:1 Topics: Breast Neoplasms; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nuclear Proteins; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinases; Transcription Factors; Tretinoin; Tumor Cells, Cultured	2003
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy, 2003, Volume: 23, Issue:7 Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Outpatients; Pioglitazone; Renal Dialysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2003
Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones. Atherosclerosis, 2003, Volume: 169, Issue:2 Topics: Cells, Cultured; Chromans; Cysteine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Eukaryotic Initiation Factors; Humans; Hypoglycemic Agents; Immunoblotting; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Methionine; Pioglitazone; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone; Umbilical Veins	2003
Glitazones and heart failure: critical appraisal for the clinician. Circulation, 2003, Aug-26, Volume: 108, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax, 2003, Volume: 58, Issue:9 Topics: Blotting, Northern; Bronchi; Bronchitis; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Humans; Hypoglycemic Agents; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Respiratory Mucosa; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors	2003
Novel PPARgamma-dependent and independent effects for thiazolidinediones. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha	2003
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology, 2004, Volume: 145, Issue:4 Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine	2004
Australian government tries to stop independent advice on diabetes drugs. BMJ (Clinical research ed.), 2003, Dec-13, Volume: 327, Issue:7428 Topics: Australia; Diabetes Mellitus, Type 2; Drug Approval; Government; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2003
Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. The Journal of investigative dermatology, 2004, Volume: 122, Issue:1 Topics: Adult; Cell Division; Cell Movement; Cells, Cultured; Epidermal Cells; Fibroblasts; Humans; Hypoglycemic Agents; Keratinocytes; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Organ Culture Techniques; Pioglitazone; Psoriasis; Rosiglitazone; Signal Transduction; Thiazolidinediones	2004
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Current medical research and opinion, 2004, Volume: 20, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2004
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease. Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:7 Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2004
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thrombosis and haemostasis, 2004, Volume: 91, Issue:4 Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone	2004
Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes, 2004, Volume: 53, Issue:4 Topics: Animals; Electron Transport Complex I; Energy Metabolism; Hypoglycemic Agents; Male; Metformin; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Potassium Chloride; Rats; Rats, Sprague-Dawley; Rosiglitazone; Rotenone; Thiazolidinediones	2004
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. The American journal of cardiology, 2004, Jun-01, Volume: 93, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrroles; Rosiglitazone; Simvastatin; Thiazolidinediones; United States; United States Food and Drug Administration	2004
Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. Prostaglandins & other lipid mediators, 2004, Volume: 73, Issue:3-4 Topics: Animals; Arachidonic Acid; Cell Membrane; Chlorocebus aethiops; COS Cells; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Humans; Lipopolysaccharides; Membrane Proteins; Mice; NIH 3T3 Cells; Phospholipases A; Phosphorylation; Pioglitazone; PPAR gamma; Prostaglandin-Endoperoxide Synthases; Rosiglitazone; Thiazolidinediones; Thromboxane A2; U937 Cells	2004
Expression of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by thiazolidinediones: an exercise-like effect? Diabetologia, 2004, Volume: 47, Issue:9 Topics: Animals; Carrier Proteins; Gene Expression Regulation; Ion Channels; Male; Mitochondrial Proteins; Muscle, Skeletal; Physical Conditioning, Animal; Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Uncoupling Protein 3	2004
Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochemical and biophysical research communications, 2004, Oct-22, Volume: 323, Issue:3 Topics: Cell Differentiation; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Macrophages; Pioglitazone; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazolidinediones	2004
Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes, 2004, Volume: 53, Issue:10 Topics: Cells, Cultured; Endothelium, Vascular; Humans; Hypoglycemic Agents; NF-kappa B; Pioglitazone; Promoter Regions, Genetic; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Umbilical Veins	2004
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut, 2004, Volume: 53, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Male; Matrix Metalloproteinases; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Pioglitazone; Plasminogen Activators; PPAR gamma; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured	2004
Generic, highly selective and robust capillary electrophoresis method for separation of a racemic mixture of glitazone compounds. Journal of chromatography. A, 2004, Sep-17, Volume: 1049, Issue:1-2 Topics: Cyclodextrins; Electrolytes; Electrophoresis, Capillary; Hypoglycemic Agents; Indicators and Reagents; Pioglitazone; Quinazolines; Reproducibility of Results; Rosiglitazone; Solutions; Stereoisomerism; Tablets; Thiazolidinediones	2004
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anti-cancer drugs, 2004, Volume: 15, Issue:10 Topics: Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Humans; Ligands; Multiple Myeloma; Pioglitazone; PPAR gamma; Prostaglandin D2; Rosiglitazone; Thiazolidinediones	2004
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats. World journal of gastroenterology, 2004, Dec-01, Volume: 10, Issue:23 Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; Glutathione Transferase; Hypoglycemic Agents; Immunohistochemistry; Ligands; Liver Neoplasms; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone	2004
Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. The Medical journal of Australia, 2004, Nov-15, Volume: 181, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides	2004
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. Analytical biochemistry, 2004, Dec-15, Volume: 335, Issue:2 Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts	2004
Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004, Dec-01, Volume: 24, Issue:48 Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anilides; Animals; Aspartic Acid Endopeptidases; Cell Line; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Chromans; Culture Media, Conditioned; Endopeptidases; Humans; Kidney; Mice; Neuroblastoma; Neuroglia; Neurons; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Processing, Post-Translational; Receptor, Notch1; Receptors, Cell Surface; Recombinant Fusion Proteins; Retinoid X Receptors; Rosiglitazone; Thiazolidinediones; Transcription Factors; Tretinoin; Troglitazone	2004
Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:3 Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adult; Aged; Cell Division; Cell Line, Tumor; Female; Humans; Hypoglycemic Agents; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured	2005
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Liver Failure; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2005
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:2 Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:8 Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eosinophils; Female; Gene Expression; Gene Expression Regulation; Interleukin-13; Interleukin-4; Interleukin-5; Lung; Methacholine Chloride; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphatidylinositol 3-Kinases; Phosphorylation; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Trachea; Transfection	2005
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:8 Topics: Aryl Hydrocarbon Hydroxylases; Automation; Chromans; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzyme Reactivators; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Pharmaceutical Preparations; Pioglitazone; Reproducibility of Results; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thrombosis and haemostasis, 2005, Volume: 93, Issue:5 Topics: Aorta; Apoptosis; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Chaperonin 60; Chromans; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Endothelium, Vascular; Enzyme Activation; Humans; Hypoglycemic Agents; Ligands; Microscopy, Phase-Contrast; Mitochondria; Pioglitazone; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; von Willebrand Factor	2005
Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. European journal of medicinal chemistry, 2005, Volume: 40, Issue:9 Topics: Animals; Cell Line; Drug Design; Drug Evaluation, Preclinical; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Mice, Mutant Strains; Models, Chemical; Pioglitazone; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2005
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocrine-related cancer, 2005, Volume: 12, Issue:2 Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Chromans; Pioglitazone; PPAR gamma; Radiation-Sensitizing Agents; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Swine; Symporters; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms; Troglitazone	2005
Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochemical and biophysical research communications, 2005, Aug-19, Volume: 334, Issue:1 Topics: Cell Line; Endothelial Cells; Humans; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Tumor Necrosis Factor-alpha	2005
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:9 Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Animal; Dyslipidemias; Female; Fenofibrate; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Mice; Mice, Mutant Strains; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
Effectiveness and side effects of thiazolidinediones for type 2 diabetes. The Medical journal of Australia, 2005, May-02, Volume: 182, Issue:9 Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2005
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention. Cardiology, 2005, Volume: 104, Issue:2 Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Rosiglitazone; Stents; Survival Rate; Thiazolidinediones	2005
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. European journal of pharmacology, 2005, Sep-05, Volume: 519, Issue:1-2 Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Metformin; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors	2005
Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:11 Topics: Adult; Cells, Cultured; Estradiol; Female; Gonadal Steroid Hormones; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1; Middle Aged; Ovary; Pioglitazone; PPAR gamma; Progesterone; Rosiglitazone; Testosterone; Thiazolidinediones	2005
Rating the severity of the medical consequences of drug-induced liver injury. Regulatory toxicology and pharmacology : RTP, 2005, Volume: 43, Issue:2 Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Pioglitazone; Risk Assessment; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones; Troglitazone	2005
Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. Molecular pharmacology, 2005, Volume: 68, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eosinophils; Immunoglobulin E; Inflammation; Interleukin-10; Interleukins; Lung; Mice; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
Leukopenia and thrombocytopenia caused by thiazolidinediones. Annals of internal medicine, 2005, Sep-20, Volume: 143, Issue:6 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Leukopenia; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thrombocytopenia	2005
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy, 2005, Volume: 25, Issue:10 Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Middle Aged; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Thiazolidinediones in type 2 diabetes--have they lived up to expectations? Journal of the Indian Medical Association, 2005, Volume: 103, Issue:6 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2005
Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology, 2006, Volume: 147, Issue:2 Topics: Adipocytes; Animals; Cell Line; Cell Line, Tumor; Hepatocytes; Humans; Hypoglycemic Agents; Liver; Male; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Sp1 Transcription Factor; Statistics, Nonparametric; Stem Cells; Sterol Esterase; Thiazolidinediones; Transcriptional Activation; Up-Regulation	2006
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Nov-03, Volume: 125, Issue:21 Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones	2005
FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. Journal of pharmacological sciences, 2005, Volume: 99, Issue:4 Topics: Benzimidazoles; CREB-Binding Protein; Genes, Reporter; Glutathione; Histone Acetyltransferases; Humans; Hybrid Cells; Hypoglycemic Agents; Ligands; Nuclear Receptor Coactivator 1; Pioglitazone; Plasmids; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcriptional Activation	2005
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al. Diabetes care, 2005, Volume: 28, Issue:12 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Research Design; Rosiglitazone; Thiazolidinediones	2005
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European journal of pharmacology, 2006, Jan-13, Volume: 530, Issue:1-2 Topics: Animals; Brain Ischemia; Cyclooxygenase 2; Hippocampus; Inflammation; Injections, Intravenous; Lipid Peroxidation; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Oxidative Stress; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Reperfusion Injury; Rosiglitazone; Signal Transduction; Thiazolidinediones	2006
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats. Clinical and experimental pharmacology & physiology, 2005, Volume: 32, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan	2005
Type 2 diabetes, psoriasis and thiazolidinediones. International journal of clinical practice, 2006, Volume: 60, Issue:3 Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Psoriasis; Rosiglitazone; Thiazolidinediones	2006
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p Biomedical chromatography : BMC, 2006, Volume: 20, Issue:10 Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones	2006
Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:3 Topics: Benzimidazoles; Glutathione; Hypoglycemic Agents; Kinetics; Ligands; Molecular Conformation; Peptide Hydrolases; Pioglitazone; Plasmids; PPAR gamma; Rosiglitazone; Spectrometry, Fluorescence; Thiazolidinediones	2006
Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population. Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:2 Topics: Diabetes Mellitus, Type 2; Drug Utilization; Fee-for-Service Plans; Female; Health Care Costs; Health Services; Humans; Hypoglycemic Agents; Insulin; Insurance Claim Review; Male; Medicaid; Middle Aged; Patient Compliance; Pioglitazone; Polypharmacy; Rosiglitazone; Thiazolidinediones	2006
Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Synergism; Female; Humans; Hypoglycemic Agents; International Normalized Ratio; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones; Warfarin	2006
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Benzimidazoles; Cell Differentiation; Chlorocebus aethiops; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 3; Gels; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Mice; Obesity; Pioglitazone; Plasmids; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides	2006
Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes care, 2006, Volume: 29, Issue:6 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2006
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. British journal of pharmacology, 2006, Volume: 148, Issue:5 Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expression; Gluconeogenesis; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Glycogen; Muscles; Obesity; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Propionates; Pyrimidines; Rats; Rats, Wistar; Rosiglitazone; Sodium Glutamate; Thiazolidinediones	2006
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:1 Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; NF-kappa B; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1	2006
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:10 Topics: Algorithms; Carbamazepine; Cell Line; Cell Proliferation; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Nifedipine; Phenobarbital; Phenytoin; Pioglitazone; Reproducibility of Results; Rifampin; Rosiglitazone; Sulfinpyrazone; Thiazolidinediones	2006
15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Molecular cancer therapeutics, 2006, Volume: 5, Issue:7 Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Gene Expression; Humans; Jurkat Cells; Membrane Glycoproteins; Neoplasms; Pioglitazone; PPAR gamma; Prostaglandin D2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA Stability; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2006
[Glitazone treatment of type 2 diabetes mellitus]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2006, Aug-10, Volume: 126, Issue:15 Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Weight Gain	2006
Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chemical research in toxicology, 2006, Volume: 19, Issue:8 Topics: Animals; Chromans; Chromatography, Liquid; Glutathione; Humans; Hypoglycemic Agents; In Vitro Techniques; Isotope Labeling; Mass Spectrometry; Microsomes, Liver; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone	2006
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clinical endocrinology, 2006, Volume: 65, Issue:3 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Humans; Immunohistochemistry; Middle Aged; Molecular Sequence Data; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Pituitary Neoplasms; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones	2006
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anti-cancer drugs, 2006, Volume: 17, Issue:7 Topics: Annexin A5; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Humans; Ligands; Lymphoma, Mantle-Cell; Pioglitazone; PPAR gamma; Prostaglandin D2; Rosiglitazone; Thiazolidinediones	2006
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Molecular diversity, 2006, Volume: 10, Issue:3 Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Liver Neoplasms; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone	2006
Rosiglitazone inhibits mouse liver regeneration. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:14 Topics: Animals; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation; Interleukin-6; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; S-Phase Kinase-Associated Proteins; Signal Transduction; STAT3 Transcription Factor; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Vasodilator Agents	2006
Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Molecular pharmacology, 2007, Volume: 71, Issue:3 Topics: 3-Hydroxysteroid Dehydrogenases; Adrenal Glands; Androgens; Base Sequence; Cells, Cultured; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Humans; Hypoglycemic Agents; Molecular Sequence Data; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; RNA, Messenger; Rosiglitazone; Steroid 17-alpha-Hydroxylase; Thiazolidinediones	2007
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics, 2007, Volume: 25, Issue:1 Topics: Blood Glucose; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Models, Economic; Monte Carlo Method; Pioglitazone; Rosiglitazone; Thiazolidinediones; United Kingdom	2007
Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark. Health care analysis : HCA : journal of health philosophy and policy, 2006, Volume: 14, Issue:2 Topics: Decision Making; Denmark; Diabetes Mellitus, Type 2; Health Care Costs; Health Policy; Humans; Hypoglycemic Agents; Pioglitazone; Reimbursement Mechanisms; Rosiglitazone; Thiazolidinediones	2006
Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones. The Journal of pharmacy and pharmacology, 2006, Volume: 58, Issue:12 Topics: Aged; Cromakalim; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Mammary Arteries; Middle Aged; Nitroprusside; Phenylephrine; Pioglitazone; Potassium Channel Blockers; Potassium Chloride; Rosiglitazone; Thiazolidinediones; Vasoconstriction	2006
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacological research, 2007, Volume: 55, Issue:5 Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Prediabetic State; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Streptozocin; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents	2007
Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:6 Topics: Cells, Cultured; Female; Granulosa Cells; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Receptor Substrate Proteins; Ovary; Phosphoproteins; Pioglitazone; PPAR gamma; Receptor, Insulin; Rosiglitazone; Signal Transduction; Stromal Cells; Theca Cells; Thiazolidinediones	2007
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. International journal of oncology, 2007, Volume: 30, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Pioglitazone; PPAR gamma; Receptors, CXCR4; Rosiglitazone; Thiazolidinediones	2007
Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3 Topics: Acyl-CoA Oxidase; Adipocytes, White; Adipose Tissue; Administration, Oral; Animals; Benzimidazoles; Biological Transport; Cell Count; Cell Size; Epididymis; Fatty Acid-Binding Proteins; Gene Expression; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2007
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. Journal of neurochemistry, 2007, Volume: 101, Issue:1 Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Encephalitis; Hypertension; Intercellular Adhesion Molecule-1; Ischemic Attack, Transient; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neuroprotective Agents; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Superoxide Dismutase-1; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones	2007
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Humans; Hydroxyprostaglandin Dehydrogenases; Hypoglycemic Agents; Membrane Proteins; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Up-Regulation	2007
Diabetes drugs tied to fractures in women. JAMA, 2007, Apr-18, Volume: 297, Issue:15 Topics: Chromans; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone	2007
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei medical journal, 2007, Apr-30, Volume: 48, Issue:2 Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Pioglitazone; Rats; Rats, Long-Evans; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A	2007
Hospital admission associated with Medicare Part D "doughnut hole". American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, May-15, Volume: 64, Issue:10 Topics: Aged; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Medicare; Metformin; Patient Readmission; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC medicine, 2007, Jun-21, Volume: 5 Topics: Age Distribution; Causality; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; New Hampshire; New York; Pioglitazone; Prevalence; Rosiglitazone; Sex Distribution; Thiazolidinediones; Vermont	2007
Pioglitazone: an anti-diabetic compound with anti-aging properties. Biogerontology, 2007, Volume: 8, Issue:6 Topics: Animals; Basal Metabolism; Dose-Response Relationship, Drug; Drosophila melanogaster; Fertility; Glipizide; Hypoglycemic Agents; Insulin; Longevity; Metformin; Models, Biological; Pioglitazone; Population Density; Research Design; Rosiglitazone; Sexual Behavior, Animal; Signal Transduction; Thiazolidinediones; Time Factors	2007
Thiazolidinediones and cardiovascular disease. The Medical letter on drugs and therapeutics, 2007, Jul-16, Volume: 49, Issue:1265 Topics: Animals; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Oct-01, Volume: 857, Issue:2 Topics: Chromans; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Lipids; Membranes, Artificial; Octanols; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Troglitazone; Water	2007
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:10 Topics: Acute Disease; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2007
In clarification. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:10 Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Options sought after drug study. Patients who take rosiglitazone might consider pioglitazone instead. Heart advisor, 2007, Volume: 10, Issue:7 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems. Harvard women's health watch, 2007, Volume: 14, Issue:12 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics, 2007, Volume: 25, Issue:9 Topics: Diabetes Mellitus, Type 2; Health Care Costs; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. European journal of pharmacology, 2007, Dec-01, Volume: 575, Issue:1-3 Topics: Acetylcholine; Animals; Aorta; Dose-Response Relationship, Drug; Endothelium, Vascular; Hypertension; Indomethacin; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phenylephrine; Pioglitazone; Prostaglandins; Rats; Rats, Inbred SHR; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents	2007
Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA, 2007, Sep-12, Volume: 298, Issue:10 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2007
Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:6 Topics: Animals; Blood Glucose; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Hypoglycemic Agents; Mice; Mice, Obese; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE. Journal of pharmaceutical and biomedical analysis, 2008, Jan-07, Volume: 46, Issue:1 Topics: Algorithms; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Molecular Structure; Pioglitazone; Rosiglitazone; Solutions; Stereoisomerism; Technology, Pharmaceutical; Thiazolidinediones; Time Factors	2008
Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus. Clinical therapeutics, 2007, Volume: 29, Issue:6 Pt 1 Topics: Adolescent; Adult; Databases, Factual; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Health Care Costs; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Medication Adherence; Middle Aged; Multivariate Analysis; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States	2007
Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:12 Topics: Coronary Disease; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus. Clinical therapeutics, 2007, Volume: 29 Spec No Topics: Adult; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Health Care Surveys; Health Services; Hospitalization; Humans; Hypoglycemic Agents; Linear Models; Male; Medicaid; Middle Aged; Multivariate Analysis; North Carolina; Patient Compliance; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome	2007
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA, 2007, Dec-12, Volume: 298, Issue:22 Topics: Aged; Aged, 80 and over; Cause of Death; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones	2007
Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs). The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2008,Winter, Volume: 15, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Formularies as Topic; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Male; Medical Records Systems, Computerized; Middle Aged; Pioglitazone; Quebec; Retrospective Studies; Risk Factors; Rosiglitazone; Socioeconomic Factors; Thiazolidinediones; Thiazolidines	2008
Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis research & therapy, 2008, Volume: 10, Issue:1 Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Cartilage, Articular; Cytokines; Dose-Response Relationship, Drug; Fever; Fibroblast Growth Factor 2; Hindlimb; Hypoglycemic Agents; Incidence; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred Lew; RNA, Messenger; Rosiglitazone; Synovial Membrane; Synovitis; Thiazolidinediones; Weight Gain	2008
Glitazones and your heart, revisited. Diabetes forecast, 2007, Volume: 60, Issue:13 Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
[Glitazone - mailing no 4. In response to DMW 49/2007]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:6 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect]. MMW Fortschritte der Medizin, 2007, Dec-06, Volume: 149, Issue:49-50 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Publishing; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia, 2008, Volume: 51, Issue:4 Topics: Animals; Blood Pressure; Disease Models, Animal; Heart; KATP Channels; Pioglitazone; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation	2008
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:8 Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2008
Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo. Biochemical and biophysical research communications, 2008, Jun-27, Volume: 371, Issue:2 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Caspase 3; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Humans; Ki-67 Antigen; Mice; Nerve Growth Factor; Neurons; PC12 Cells; Pheochromocytoma; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones	2008
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:12 Topics: Adipokines; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult	2008
Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. Journal of molecular graphics & modelling, 2008, Volume: 27, Issue:2 Topics: Computer Simulation; Docosahexaenoic Acids; Humans; Hypoglycemic Agents; Ligands; Models, Molecular; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Protein Binding; Retinoid X Receptor alpha; Rosiglitazone; Thermodynamics; Thiazolidinediones	2008
Initiating antidiabetic drug therapy. Clinical therapeutics, 2008, Volume: 30, Issue:5 Topics: Diabetes Mellitus, Type 2; Health Care Costs; Humans; Hypoglycemic Agents; Medicaid; Pioglitazone; Rosiglitazone; Thiazolidinediones; Time Factors; United States	2008
Are prescribing patterns of antidiabetic medications influenced by fears of litigation? Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:8 Topics: Drug Prescriptions; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:8 Topics: Adult; Aged; Biguanides; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Myocardial Ischemia; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors	2008
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. Journal of lipid research, 2008, Volume: 49, Issue:12 Topics: Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipogenesis; Male; Pilot Projects; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. American journal of physiology. Endocrinology and metabolism, 2008, Volume: 295, Issue:5 Topics: Adipocytes, White; Adipose Tissue, White; Angiopoietin-Like Protein 4; Angiopoietins; Animals; Antigens, CD; Cadherins; Capillaries; Cells, Cultured; Culture Media, Conditioned; Epididymis; Gene Expression; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neovascularization, Physiologic; Obesity; Pioglitazone; PPAR gamma; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B	2008
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart (British Cardiac Society), 2009, Volume: 95, Issue:1 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference? Journal of the American College of Cardiology, 2008, Sep-02, Volume: 52, Issue:10 Topics: Diabetes Mellitus, Type 2; Endothelins; Humans; Inflammation; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1	2008
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clinical endocrinology, 2009, Volume: 70, Issue:6 Topics: Carcinoma; Cell Proliferation; Growth Inhibitors; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Tumor Cells, Cultured	2009
Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes. Chemical research in toxicology, 2008, Volume: 21, Issue:10 Topics: Acetylcysteine; Animals; Chromans; Electrochemistry; Humans; Magnetic Resonance Spectroscopy; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone	2008
Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Oct-01, Volume: 65, Issue:19 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; PPAR gamma; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones	2008
PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis, 2008, Volume: 11, Issue:4 Topics: Animals; Cells, Cultured; Chemotaxis; Chick Embryo; Chorioallantoic Membrane; Endothelial Cells; Fibroblast Growth Factor 2; Humans; Models, Biological; Neovascularization, Physiologic; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A	2008
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Current medical research and opinion, 2008, Volume: 24, Issue:11 Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States	2008
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clinica chimica acta; international journal of clinical chemistry, 2009, Volume: 400, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Edema; Female; Genomics; Genotype; Humans; Hypoglycemic Agents; Male; Middle Aged; Phenotype; Pioglitazone; Polymorphism, Single Nucleotide; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2009
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Archives of internal medicine, 2008, Nov-24, Volume: 168, Issue:21 Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2008
Thiazolidinediones: do harms outweigh benefits? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Jan-06, Volume: 180, Issue:1 Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones; Treatment Outcome	2009
Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:4 Topics: Animals; Epithelial Sodium Channels; Kidney Medulla; Kidney Tubules, Collecting; Mice; Patch-Clamp Techniques; Pioglitazone; Rosiglitazone; Thiazolidinediones; Weight Gain	2009
Glitazone use associated with diabetic macular edema. American journal of ophthalmology, 2009, Volume: 147, Issue:4 Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Macular Edema; Middle Aged; Pioglitazone; PPAR gamma; Prospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3 Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:6 Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2009
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2009
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:5 Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Graves Disease; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Interferon-gamma; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroid Gland; Tumor Necrosis Factor-alpha	2009
Thiazolidinediones: antidiabetic agents with effects on bone. Joint bone spine, 2009, Volume: 76, Issue:3 Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Male; Mice; Osteoporosis; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Rosiglitazone; Thiazolidinediones	2009
Thiazolidinedione use and the risk of fractures. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Apr-14, Volume: 180, Issue:8 Topics: Bone Density; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Greece; Humans; Hypoglycemic Agents; Incidence; Male; Odds Ratio; Pioglitazone; Reference Values; Risk Assessment; Rosiglitazone; Thiazolidinediones	2009
Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:1 Topics: Animals; Cell Line, Tumor; Chromans; Humans; Luciferases, Renilla; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone	2009
Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:8 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Consumer Product Safety; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Ontario; Pioglitazone; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug safety, 2009, Volume: 32, Issue:5 Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones	2009
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Current medical research and opinion, 2009, Volume: 25, Issue:6 Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States	2009
Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovascular therapeutics, 2009,Summer, Volume: 27, Issue:2 Topics: Attitude of Health Personnel; Awareness; Cardiovascular Diseases; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Information Services; Evidence-Based Medicine; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Mass Media; Meta-Analysis as Topic; Pioglitazone; Practice Patterns, Physicians'; Risk Assessment; Rosiglitazone; Scotland; Surveys and Questionnaires; Thiazolidinediones; Time Factors	2009
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochemistry international, 2009, Volume: 55, Issue:7 Topics: Blotting, Western; Cell Death; Cell Line, Tumor; DNA, Mitochondrial; Glucose; Humans; Hypoglycemic Agents; Malonates; Membrane Potentials; Mitochondria; Neurons; Neuroprotective Agents; Pioglitazone; PPAR gamma; Pyruvic Acid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Stimulation, Chemical; Thiazolidinediones	2009
Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion. American journal of physiology. Gastrointestinal and liver physiology, 2009, Volume: 297, Issue:1 Topics: Administration, Oral; Animals; Calcium; Carbachol; Chlorides; Cholera Toxin; Colforsin; Colon; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Disease Models, Animal; Electric Impedance; Female; Gastrointestinal Agents; HT29 Cells; Humans; Ileum; Intermediate-Conductance Calcium-Activated Potassium Channels; Intestinal Mucosa; Intestinal Secretions; Intestines; Jejunum; KCNQ1 Potassium Channel; Mice; Pioglitazone; PPAR gamma; Rosiglitazone; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Thiazolidinediones; Time Factors	2009
Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. Journal of neurochemistry, 2009, Volume: 109, Issue:6 Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Calcium; Calcium Channels; Calcium Signaling; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Embryo, Mammalian; Enzyme-Linked Immunosorbent Assay; Excitatory Amino Acid Antagonists; Female; Hippocampus; Hypoglycemic Agents; Neuroglia; Neurons; Patch-Clamp Techniques; Pioglitazone; PPAR gamma; Pregnancy; Protein Binding; Rats; Receptors, N-Methyl-D-Aspartate; Rosiglitazone; Thiazolidinediones; Time Factors	2009
Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681 Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2009
Cardiovascular risk and TZD: safe therapy for the elderly? The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2009, Volume: 24, Issue:5 Topics: Age Factors; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy, 2009, Volume: 29, Issue:7 Topics: Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones; Time Factors; United States	2009
Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PloS one, 2009, Jun-27, Volume: 4, Issue:6 Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Medical Records Systems, Computerized; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Regression Analysis; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2009
Type 2 diabetes, thiazolidinediones, and cardiovascular risk. The British journal of general practice : the journal of the Royal College of General Practitioners, 2009, Volume: 59, Issue:564 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug safety, 2009, Volume: 32, Issue:8 Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones	2009
Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Failure; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors	2009
Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. Journal of immunology (Baltimore, Md. : 1950), 2009, Sep-01, Volume: 183, Issue:5 Topics: Animals; Asthma; Disease Models, Animal; Down-Regulation; Female; Inflammation Mediators; Interleukin-17; Lung; Mice; Mice, Inbred C57BL; NF-kappa B; Ovalbumin; Pioglitazone; PPAR gamma; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones	2009
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Thiazolidinediones and fractures in men and women. Archives of internal medicine, 2009, Aug-10, Volume: 169, Issue:15 Topics: Adult; Aged; British Columbia; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk; Rosiglitazone; Sex Factors; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines	2009
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Rosiglitazone or pioglitazone in type 2 diabetes? BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues. Experimental & molecular medicine, 2009, Dec-31, Volume: 41, Issue:12 Topics: Adipocytes; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Animals; Carrier Proteins; Cell Nucleus Division; Hypoglycemic Agents; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Mitochondrial Proteins; Perilipin-1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphoproteins; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Trans-Activators; Transcription Factors; Uncoupling Protein 1	2009
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel. Molecular pharmacology, 2009, Volume: 76, Issue:6 Topics: Anilides; Animals; Benzamides; Biological Transport; Cell Survival; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Hypoglycemic Agents; Insulin; Membrane Potentials; Pioglitazone; PPAR gamma; Pyridines; Rosiglitazone; Sodium; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone	2009
Rosiglitazone and pioglitazone. Beware macular oedema. BMJ (Clinical research ed.), 2009, Sep-22, Volume: 339 Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular Edema; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS medicine, 2009, Volume: 6, Issue:9 Topics: Aged; Bone and Bones; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom	2009
Rosiglitazone and pioglitazone. Beware fractures. BMJ (Clinical research ed.), 2009, Sep-29, Volume: 339 Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo. Molecular and cellular endocrinology, 2010, Apr-12, Volume: 317, Issue:1-2 Topics: Anilides; Animals; Animals, Newborn; Gene Expression Regulation; Gene Knockdown Techniques; Glucose Transporter Type 4; Hypothalamus; Injections, Intraventricular; Mice; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Thyroid Hormone Receptors beta; Thyrotropin-Releasing Hormone; Thyroxine; Transfection; Triiodothyronine	2010
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:1 Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Ischemia; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pioglitazone; Retinal Vessels; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2010
Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1. Shock (Augusta, Ga.), 2010, Volume: 33, Issue:6 Topics: Anilides; Animals; Bone Marrow Cells; Cell Differentiation; Cell Line; Down-Regulation; Macrophages; Mice; NFATC Transcription Factors; Osteoclasts; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2010
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339 Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2009
Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. Journal of molecular modeling, 2010, Volume: 16, Issue:4 Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Models, Molecular; Pioglitazone; Quantitative Structure-Activity Relationship; Rosiglitazone; Thiazolidinediones	2010
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists. Analytical and bioanalytical chemistry, 2010, Volume: 396, Issue:5 Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques	2010
Lipid metabolism. Current opinion in lipidology, 2010, Volume: 21, Issue:1 Topics: Antipsychotic Agents; Humans; Lipid Metabolism; Lipids; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2010
Effects of peroxisome proliferator-activated receptor gamma agonists on Na+ transport and activity of the kinase SGK1 in epithelial cells from lung and kidney. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Biological Transport; Cell Count; Epithelial Cells; Epithelium; Glucocorticoids; Humans; Insulin; Kidney; Lung; Phosphorylation; Phosphotransferases; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2010
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Adult; Aged; Cohort Studies; Coronary Disease; Death, Sudden; Female; Follow-Up Studies; Heart Rate; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; United States	2009
Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovascular research, 2010, Aug-01, Volume: 87, Issue:3 Topics: Anilides; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Northern; Blotting, Western; Caspase 3; Cell Line; Cell Survival; Disease Models, Animal; Down-Regulation; Gene Expression Profiling; Mice; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Myocardial Reperfusion Injury; Myocardium; Oligonucleotide Array Sequence Analysis; Oligonucleotides, Antisense; Phosphorylation; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Rosiglitazone; Thiazolidinediones; Time Factors; Transfection	2010
A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:3 Topics: Advisory Committees; American Heart Association; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Pioglitazone; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones; United States	2010
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Journal of the American College of Cardiology, 2010, Apr-27, Volume: 55, Issue:17 Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States	2010
Inverse association of PPARγ agonists use and high grade glioma development. Journal of neuro-oncology, 2010, Volume: 100, Issue:2 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Pioglitazone; PPAR gamma; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2010
Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants. Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:4 Topics: Animals; Cholesterol, HDL; Glycated Hemoglobin; Humans; Lipase; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tissue Culture Techniques	2010
Avandia outcome may signal change in epidemiologists' sway. Nature medicine, 2010, Volume: 16, Issue:6 Topics: Clinical Trials as Topic; Drug Approval; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:7 Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Managed Care Programs; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Rosiglitazone and the case for safety over certainty. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Decision Making; Diabetes Mellitus, Type 2; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2010
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Medicare Part D; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Stroke; Thiazolidinediones; United States	2010
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adult; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2010
Thiazolidinediones and fractures: evidence from translating research into action for diabetes. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:10 Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical	2010
Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9 Topics: Body Mass Index; Cell Respiration; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Pioglitazone; Rosiglitazone; Thiazolidinediones	2010
Drug safety. Planned study of Avandia in doubt after FDA review. Science (New York, N.Y.), 2010, Jul-23, Volume: 329, Issue:5990 Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Informed Consent; Patient Selection; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Effective approach. Nature, 2010, Jul-22, Volume: 466, Issue:7305 Topics: Diabetes Mellitus; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Health Care Rationing; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones	2010
Revisiting the rosiglitazone story--lessons learned. The New England journal of medicine, 2010, Aug-26, Volume: 363, Issue:9 Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Labeling; Government Regulation; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Odds Ratio; Pioglitazone; PPAR gamma; Product Recalls and Withdrawals; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Neuroscience, 2010, Oct-27, Volume: 170, Issue:3 Topics: Animals; Behavior, Animal; Blood Pressure; Brain; Brain Ischemia; Cell Adhesion Molecules; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Infarction, Middle Cerebral Artery; Leukocytes; Male; Neuroprotective Agents; Pioglitazone; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion; Rosiglitazone; Stroke; Thiazolidinediones	2010
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice. Life sciences, 2010, Sep-25, Volume: 87, Issue:13-14 Topics: Acyl-CoA Dehydrogenase; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; CD36 Antigens; Cholesterol; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; Fatty Acid Transport Proteins; Gene Expression Regulation; Hypoglycemic Agents; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides	2010
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5 Topics: Female; Heart Failure; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Pioglitazone; Population Groups; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States	2010
Differential effects of PPARgamma ligands on oxidative stress-induced death of retinal pigmented epithelial cells. Investigative ophthalmology & visual science, 2011, Feb-22, Volume: 52, Issue:2 Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line; Cell Survival; Drug Synergism; Gene Silencing; Humans; Ligands; Microarray Analysis; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Rosiglitazone; tert-Butylhydroperoxide; Thiazolidinediones; Transfection	2011
Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein. British journal of pharmacology, 2010, Volume: 161, Issue:4 Topics: Adenosine Triphosphate; Apoptosis; Carrier Proteins; Cell Survival; Chromans; Gene Expression Regulation; Heat-Shock Proteins; Hep G2 Cells; Humans; Hypoglycemic Agents; Mitochondria, Liver; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; Reactive Oxygen Species; RNA-Binding Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone	2010
PPARgamma-dependent regulation of adenylate cyclase 6 amplifies the stimulatory effect of cAMP on renin gene expression. Molecular endocrinology (Baltimore, Md.), 2010, Volume: 24, Issue:11 Topics: Adenylyl Cyclases; Animals; Base Sequence; Binding Sites; Cell Line; Consensus Sequence; Cyclic AMP; Drug Synergism; Enzyme Activators; Gene Expression Regulation; Humans; Introns; Mice; Molecular Sequence Data; Oligonucleotides; Pioglitazone; Pituitary Adenylate Cyclase-Activating Polypeptide; PPAR gamma; Promoter Regions, Genetic; Renin; Rosiglitazone; Thiazolidinediones	2010
Meta-analysis and moderation. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:10 Topics: Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Scopolamine Derivatives; Thiazolidinediones; Tiotropium Bromide	2010
Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. Journal of molecular endocrinology, 2011, Volume: 46, Issue:1 Topics: Adrenal Cortex; Aldosterone; Benzophenones; Benzylamines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cell Line; Cytochrome P-450 CYP11B2; Gene Expression; Gene Expression Regulation, Enzymologic; Humans; Ionomycin; Mutation; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Sulfonamides; Thiazolidinediones; Transcription, Genetic; Tyrosine; Zona Glomerulosa	2011
Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia, 2011, Volume: 59, Issue:2 Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adult Stem Cells; Animals; Bromodeoxyuridine; Caspase 3; Cell Differentiation; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cerebral Ventricles; Doublecortin Domain Proteins; Glial Fibrillary Acidic Protein; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Neural Cell Adhesion Molecule L1; Neural Stem Cells; Neuropeptides; Olfactory Bulb; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Sialic Acids; Thiazolidinediones	2011
Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biological psychiatry, 2011, Apr-01, Volume: 69, Issue:7 Topics: Adrenergic alpha-2 Receptor Antagonists; Alcohol Drinking; Alcohols; Analysis of Variance; Anilides; Animals; Behavior, Animal; Blood Glucose; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Food Preferences; Gene Expression Regulation; Hypoglycemic Agents; Male; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Self Administration; Substance Withdrawal Syndrome; Thiazolidinediones; Yohimbine	2011
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PloS one, 2011, Jan-21, Volume: 6, Issue:1 Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone	2011
Switching from rosiglitazone: thinking outside the class. JAMA, 2011, Feb-23, Volume: 305, Issue:8 Topics: Blood Glucose; Cardiovascular Diseases; Decision Making; Diabetes Mellitus; Drug Labeling; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2011
Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2011, Volume: 43, Issue:4 Topics: Androgens; Aromatase; Cells, Cultured; Down-Regulation; Estrogens; Estrone; Female; Granulosa Cells; Humans; Pioglitazone; Protein Binding; Rosiglitazone; Thiazolidinediones	2011
Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes research and clinical practice, 2011, Volume: 93, Issue:1 Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States	2011
Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts. The Journal of biological chemistry, 2011, May-27, Volume: 286, Issue:21 Topics: Cell Adhesion; Cells, Cultured; Fibroblasts; Fibrosis; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hypoglycemic Agents; Inflammation; Ligands; Orbit; Orbital Diseases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Transforming Growth Factor beta	2011
Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning. International journal of clinical practice, 2011, Volume: 65, Issue:5 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United Kingdom	2011
Rosiglitazone saga. Demonisation of rosiglitazone. BMJ (Clinical research ed.), 2011, Apr-21, Volume: 342 Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes. Diabetes research and clinical practice, 2011, Volume: 93, Issue:1 Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones	2011
Novel ligands that target the mitochondrial membrane protein mitoNEET. Journal of molecular graphics & modelling, 2011, Volume: 29, Issue:7 Topics: Binding Sites; Databases, Protein; Humans; Hydrogen Bonding; Hypoglycemic Agents; Ligands; Mitochondria; Mitochondrial Proteins; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Pioglitazone; PPAR gamma; Protein Binding; Protein Conformation; Recombinant Proteins; Rosiglitazone; Thiazolidinediones	2011
[Glycemic control and cardiovascular benefit: what do we know today?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:19 Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones	2011
[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?]. Revue medicale de Liege, 2011, Volume: 66, Issue:3 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Failure	2011
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC clinical pharmacology, 2011, May-24, Volume: 11 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Edema; Female; France; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats. Neuroscience, 2011, Sep-29, Volume: 192 Topics: Animals; Dementia, Vascular; Disease Models, Animal; Hyperhomocysteinemia; Hypoglycemic Agents; Male; Maze Learning; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones	2011
Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:4 Topics: Animals; Aorta; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; In Vitro Techniques; Male; Mesenteric Arteries; Microcirculation; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Obesity; Pioglitazone; Prostaglandins; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Superoxides; Thiazolidinediones; Vascular Resistance; Vasoconstrictor Agents	2011
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. The Journal of general physiology, 2011, Volume: 138, Issue:2 Topics: Animals; Cell Line; Cell Membrane; Chromans; Drug Discovery; Gramicidin; Insulin; Ion Channels; Lipid Bilayers; Membrane Potentials; Membrane Proteins; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Sodium Channels; Thiazolidinediones; Troglitazone	2011
Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension. Pharmacology, 2011, Volume: 88, Issue:1-2 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelium, Vascular; Epinephrine; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Hypoglycemic Agents; Indomethacin; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitroprusside; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Thromboxane A2; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents	2011
Pioglitazone is a valid alternative to rosiglitazone. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Dec-01, Volume: 11, Issue:6 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones	2011
Intermittent fasting up-regulates Fsp27/Cidec gene expression in white adipose tissue. Nutrition (Burbank, Los Angeles County, Calif.), 2012, Volume: 28, Issue:3 Topics: Adipocytes; Adipose Tissue, White; Animals; CCAAT-Enhancer-Binding Protein-alpha; Fasting; Insulin; Leptin; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Up-Regulation	2012
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. International journal of oncology, 2012, Volume: 40, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays	2012
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators. Journal of medicinal chemistry, 2011, Dec-22, Volume: 54, Issue:24 Topics: Animals; Benzimidazoles; Binding Sites; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dimethadione; Drug Partial Agonism; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Mice; Models, Molecular; Mutagenesis; Nuclear Receptor Coactivators; Oxazoles; Pioglitazone; PPAR gamma; Protein Conformation; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation	2011
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. PloS one, 2011, Volume: 6, Issue:11 Topics: Animals; Blood Glucose; Dietary Fats; Fatty Acids, Omega-3; Homeostasis; Hypoglycemic Agents; Lipids; Male; Metabolomics; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome	2011
The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regulatory peptides, 2012, Feb-10, Volume: 174, Issue:1-3 Topics: Adiponectin; Animals; Body Mass Index; Insulin; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Receptors, Adiponectin; RNA; Rosiglitazone; Thiazolidinediones	2012
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PloS one, 2011, Volume: 6, Issue:12 Topics: Adenocarcinoma; Animals; Bone Marrow; Coculture Techniques; Disease Progression; Fluorescent Antibody Technique; Green Fluorescent Proteins; Humans; Hypoglycemic Agents; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myeloid Cells; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2011
2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma. Journal of cardiovascular pharmacology, 2012, Volume: 59, Issue:4 Topics: Aorta; Atherosclerosis; Cell Cycle; Cell Proliferation; Chalcones; Drug Synergism; Gene Expression Regulation; Humans; Inflammation; Lipoproteins, LDL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2012
Mining relational paths in integrated biomedical data. PloS one, 2011, Volume: 6, Issue:12 Topics: Algorithms; Computers; Data Collection; Data Mining; Databases, Factual; Humans; Hypoglycemic Agents; Ibuprofen; Medical Informatics; Models, Statistical; Myocardial Infarction; Parkinson Disease; Pioglitazone; Rosiglitazone; Software; Thiazolidinediones	2011
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PloS one, 2011, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2011
Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney. American journal of physiology. Renal physiology, 2012, Mar-01, Volume: 302, Issue:5 Topics: Abdominal Fat; Acetylation; Animals; Body Weight; Epithelial Sodium Channels; Hypoglycemic Agents; Kidney; Mice; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones	2012
Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2011, Volume: 28, Issue:5 Topics: Animals; Electron Transport Complex I; Electron Transport Complex II; Electron Transport Complex III; Hepatocytes; Hypoglycemic Agents; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxygen Consumption; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones	2011
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation, 2012, Volume: 35, Issue:4 Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Kidney; Male; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Chemokine; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2012
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug safety, 2012, Apr-01, Volume: 35, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as Topic; Databases, Factual; Eye; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Macular Edema; Male; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2012
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy. The Journal of endocrinology, 2012, Volume: 213, Issue:2 Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; Humans; Interferon-gamma; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2012
Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages. Cardiovascular research, 2012, Jun-01, Volume: 94, Issue:3 Topics: Apoptosis; Cell-Derived Microparticles; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Macrophages; Mitogen-Activated Protein Kinases; Monocytes; Pioglitazone; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2012
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3 Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; Glyburide; Hydroxy Acids; Hypoglycemic Agents; Ischemia; Ischemic Preconditioning, Myocardial; Male; Pioglitazone; Potassium Channel Blockers; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation	2012
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude. Toxicologic pathology, 2012, Volume: 40, Issue:5 Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1	2012
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug safety, 2012, Jun-01, Volume: 35, Issue:6 Topics: Adverse Drug Reaction Reporting Systems; Aged; Diabetes Mellitus, Type 2; Drug Prescriptions; Drug Utilization; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Netherlands; Pharmacies; Pioglitazone; Practice Patterns, Physicians'; Risk; Rosiglitazone; Thiazolidinediones	2012
The role of ribosylated-BSA in regulating PC12 cell viability. Cell biology and toxicology, 2012, Volume: 28, Issue:4 Topics: Animals; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fructose; Glucose; Glycation End Products, Advanced; Glycosylation; Imidazoles; Lysine; Mice; Molecular Weight; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Pioglitazone; Polysaccharides; PPAR gamma; Pyrimidines; Rats; Ribose; Rosiglitazone; Serum Albumin, Bovine; Thiazolidinediones	2012
Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice. PloS one, 2012, Volume: 7, Issue:4 Topics: Animals; CD36 Antigens; Diet, High-Fat; Fenofibrate; Gene Expression Regulation; Glucose; Lipid Metabolism; Lipid Peroxidation; Mice; Mice, Knockout; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2012
Cardioprotection from oxidative stress in the newborn heart by activation of PPARγ is mediated by catalase. Free radical biology & medicine, 2012, Jul-15, Volume: 53, Issue:2 Topics: Age Factors; Anilides; Animals; Animals, Newborn; Cardiotonic Agents; Catalase; Heart; Hydrogen Peroxide; L-Lactate Dehydrogenase; Organ Culture Techniques; Oxidative Stress; Pioglitazone; PPAR gamma; Rabbits; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation; Ventricular Function, Left	2012
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. The Journal of biological chemistry, 2012, Jul-06, Volume: 287, Issue:28 Topics: 3T3-L1 Cells; Animals; Binding, Competitive; Cells, Cultured; Female; Gene Expression; Glycolysis; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Molecular Structure; Obesity; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones	2012
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Archives of internal medicine, 2012, Jul-09, Volume: 172, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Logistic Models; Macular Edema; Male; Middle Aged; Odds Ratio; Pioglitazone; PPAR gamma; Retrospective Studies; Risk Assessment; Rosiglitazone; Thiazolidinediones	2012
Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. British journal of clinical pharmacology, 2013, Volume: 75, Issue:3 Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Labeling; Drug Prescriptions; Drug Substitution; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom	2013
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts. The British journal of dermatology, 2013, Volume: 168, Issue:1 Topics: Adult; Aged; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Female; Fibroblasts; Humans; Male; Middle Aged; Pioglitazone; PPAR gamma; Rosiglitazone; Scleroderma, Systemic; Thiazolidinediones	2013
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays	2013
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. Journal of the National Cancer Institute, 2012, Sep-19, Volume: 104, Issue:18 Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms	2012
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:6 Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subunit; Fatty Acid-Binding Proteins; Female; Femur; Insulin Resistance; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones	2012
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia, 2012, Volume: 55, Issue:11 Topics: Age Distribution; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Hip Fractures; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmacoepidemiology; Pioglitazone; Risk Factors; Rosiglitazone; Scotland; Sex Distribution; Thiazolidinediones	2012
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models. Neuroscience letters, 2012, Oct-18, Volume: 528, Issue:1 Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Injections, Intraventricular; Injections, Spinal; Metformin; Mice; Mice, Inbred ICR; Pioglitazone; Rosiglitazone; Streptozocin; Thiazolidinediones	2012
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties. European journal of pharmacology, 2012, Dec-15, Volume: 697, Issue:1-3 Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Dose-Response Relationship, Drug; Drug Design; Fatty Acid-Binding Proteins; Gene Expression Regulation; Glutathione; Humans; Hypoglycemic Agents; Liver Neoplasms; Mice; Microsomes, Liver; Molecular Structure; Phosphorylation; Pioglitazone; PPAR gamma; Protein Carbonylation; Receptor Protein-Tyrosine Kinases; Receptors, Peptide; Rosiglitazone; Structure-Activity Relationship; Succinimides; Thiazolidinediones; Troglitazone	2012
A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiology and drug safety, 2013, Volume: 22, Issue:1 Topics: Adult; Aged; Cohort Studies; Comparative Effectiveness Research; Databases, Factual; Diabetes Mellitus, Type 2; Electronic Health Records; Feasibility Studies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2013
PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha. Neuroscience, 2013, Jan-15, Volume: 229 Topics: Adenosine Triphosphate; Adenylate Kinase; Caspase 3; Cell Survival; Chromans; Humans; Mitochondria; Neural Stem Cells; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Up-Regulation	2013
Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochemical pharmacology, 2013, Feb-15, Volume: 85, Issue:4 Topics: Anilides; Animals; Chromans; Dose-Response Relationship, Drug; Enzyme Inhibitors; Femoral Artery; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitroarginine; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone; Vasoconstriction	2013
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Middle Aged; Nutrition Surveys; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States	2013
Peroxisome proliferator-activated receptor γ agonists attenuate hyperglycaemia-induced hyaluronan secretion in vascular smooth muscle cells by inhibiting PKCβ2. Cell biochemistry and biophysics, 2013, Volume: 67, Issue:2 Topics: Gene Expression Regulation; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyperglycemia; Muscle, Smooth, Vascular; Pioglitazone; PPAR gamma; Protein Kinase C beta; Protein Kinase Inhibitors; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2013
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. Journal of neurochemistry, 2013, Volume: 126, Issue:5 Topics: Animals; Blotting, Western; Cells, Cultured; Cerebral Cortex; Chromans; Cyclin-Dependent Kinase 5; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Immunoprecipitation; Neurons; Phosphorylation; Pioglitazone; PPAR gamma; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; tau Proteins; Thiazolidinediones; Transfection; Troglitazone	2013
Thiazolidinediones cause compaction of nuclear heterochromatin in the pluripotent mesenchymal cell line C3H10T1/2 when inducing an adipogenic phenotype. Analytical and quantitative cytopathology and histopathology, 2013, Volume: 35, Issue:2 Topics: Adipocytes; Adipogenesis; Alkaline Phosphatase; Animals; Cell Differentiation; Cell Line; Cell Nucleus; Core Binding Factor Alpha 1 Subunit; Gene Expression; Heterochromatin; Hypoglycemic Agents; Mesenchymal Stem Cells; Mice; Phenotype; Pioglitazone; Pluripotent Stem Cells; PPAR gamma; Rosiglitazone; Thiazolidinediones	2013
The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. The European respiratory journal, 2014, Volume: 43, Issue:2 Topics: Adrenal Cortex Hormones; Aged; Animals; Apoptosis; Chemokine CCL5; Dexamethasone; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Inflammation; Interleukin-8; Ligands; Lipopolysaccharides; Macrophages; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neutrophils; Pioglitazone; PPAR gamma; Pulmonary Disease, Chronic Obstructive; Rosiglitazone; Smoking; Thiazolidinediones; Tumor Necrosis Factor-alpha	2014
Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. Drug safety, 2013, Volume: 36, Issue:8 Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Urinary Bladder Neoplasms	2013
Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach. Journal of applied toxicology : JAT, 2014, Volume: 34, Issue:7 Topics: Benzhydryl Compounds; Humans; Peroxisome Proliferator-Activated Receptors; Phenols; Phthalic Acids; Pioglitazone; Plasticizers; Protein Conformation; Retinoid X Receptor alpha; Retinoid X Receptor beta; Retinoid X Receptor gamma; Rosiglitazone; Thiazolidinediones	2014
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study. Mutation research, 2013, Sep-18, Volume: 757, Issue:1 Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2013
Impact of thiazolidinediones on macular thickness and volume in diabetic eyes. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2013, Volume: 48, Issue:4 Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Macular Edema; Male; Middle Aged; Pilot Projects; Pioglitazone; Prospective Studies; Retina; Rosiglitazone; Subretinal Fluid; Thiazolidinediones; Tomography, Optical Coherence; Visual Acuity	2013
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Young Adult	2013
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. British journal of pharmacology, 2013, Volume: 170, Issue:5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Benzoates; Biological Transport; Breast Neoplasms; Chlorophyll; Drug Resistance, Neoplasm; Endocytosis; Female; HEK293 Cells; Humans; Kinetics; MCF-7 Cells; Neoplasm Proteins; Phosphatidylinositol 3-Kinase; Pioglitazone; PPAR gamma; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Rosiglitazone; Signal Transduction; Telmisartan; Thiazolidinediones; Transfection; Up-Regulation	2013
Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study. BMC cancer, 2013, Sep-17, Volume: 13 Topics: Adult; Aged; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Population Surveillance; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones	2013
The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2013, Volume: 20, Issue:3 Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Drug Prescriptions; Evidence-Based Medicine; Female; Formularies as Topic; Humans; Hypoglycemic Agents; Incidence; Male; Meta-Analysis as Topic; Ontario; Pioglitazone; Population Surveillance; Rosiglitazone; Thiazolidinediones	2013
Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones. Journal of proteome research, 2013, Dec-06, Volume: 12, Issue:12 Topics: 5' Flanking Region; Adenosine Monophosphate; Adenylosuccinate Synthase; Animals; Cardiomegaly; Gene Expression Regulation; Hypoglycemic Agents; Inosine; Male; Metabolomics; Multivariate Analysis; Myocardium; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Response Elements; Ribose-Phosphate Pyrophosphokinase; Rosiglitazone; Signal Transduction; Thiazolidinediones	2013
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. The American journal of pathology, 2014, Volume: 184, Issue:2 Topics: Animals; Cardiac Volume; Cardiomegaly; Diuretics; Extracellular Signal-Regulated MAP Kinases; Furosemide; Gene Expression Regulation; Glucose; Insulin; Lipid Metabolism; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; Rosiglitazone; Signal Transduction; Spironolactone; Thiazolidinediones; Trichlormethiazide; Ultrasonography	2014
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model. Journal of medicinal food, 2013, Volume: 16, Issue:12 Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones	2013
Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology, 2014, Volume: 142, Issue:3 Topics: Animals; Apolipoproteins E; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2014
Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats. Pediatric research, 2014, Volume: 75, Issue:5 Topics: Administration, Inhalation; Animals; Animals, Newborn; Bronchoalveolar Lavage; Cell Differentiation; Female; Hyperoxia; Lung; Lung Injury; Male; Nebulizers and Vaporizers; Pioglitazone; PPAR gamma; Pulmonary Alveoli; Rats; Rats, Sprague-Dawley; Rosiglitazone; Surface-Active Agents; Thiazolidinediones	2014
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PloS one, 2014, Volume: 9, Issue:1 Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides	2014
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PloS one, 2014, Volume: 9, Issue:2 Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2014
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. BMC health services research, 2014, Apr-04, Volume: 14 Topics: Adverse Drug Reaction Reporting Systems; Australia; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones	2014
A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC medical genomics, 2014, Jun-17, Volume: 7 Topics: Animals; Cardiomegaly; Diet, High-Fat; Gene Expression Profiling; Gene Expression Regulation; Genome; Male; Mice; Myocardium; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; Receptors, LDL; Rosiglitazone; Systems Biology; Thiazolidinediones; Transcription Factors; Transcriptome	2014
Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis. Annals of transplantation, 2014, Aug-08, Volume: 19 Topics: Adult; Cohort Studies; Female; Finland; Humans; Hypoglycemic Agents; Life Style; Liver Transplantation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2014
Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:4 Topics: Alzheimer Disease; Animals; Body Weight; Brain; Disease Models, Animal; Exploratory Behavior; Female; Hypoglycemic Agents; Learning Disabilities; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neuroimmunomodulation; Neuroprotective Agents; Nootropic Agents; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rosiglitazone; Spatial Learning; tau Proteins; Thiazolidinediones	2015
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:9 Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult	2014
Metabolic profiling of CHO-AβPP695 cells revealed mitochondrial dysfunction prior to amyloid-β pathology and potential therapeutic effects of both PPARγ and PPARα Agonisms for Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2015, Volume: 44, Issue:1 Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Differentiation; Cell Proliferation; CHO Cells; Cricetulus; Discriminant Analysis; Extracellular Fluid; Gene Expression Regulation; Glucose; Humans; Mice; Multivariate Analysis; Peptide Fragments; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Time Factors; Transfection	2015
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes. Experimental dermatology, 2015, Volume: 24, Issue:1 Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone	2015
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia, 2015, Volume: 58, Issue:3 Topics: Aged; British Columbia; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Rosiglitazone; Scotland; Thiazolidinediones; Urinary Bladder Neoplasms	2015
Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition. Journal of physiology and biochemistry, 2015, Volume: 71, Issue:3 Topics: Adipocytes; Adult; Amine Oxidase (Copper-Containing); Anti-Inflammatory Agents; Benzylamines; Cell Adhesion Molecules; Drug Evaluation, Preclinical; Female; Humans; Hydrogen Peroxide; Middle Aged; Monoamine Oxidase Inhibitors; Pioglitazone; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Tyramine	2015
The Yin and the Yang of CV risks in patients with diabetes. The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No. Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2014
Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. Toxicology and applied pharmacology, 2015, Apr-15, Volume: 284, Issue:2 Topics: Cell Line, Tumor; Chromans; DNA, Mitochondrial; Electron Transport; Humans; Hypoglycemic Agents; Liver; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Pioglitazone; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Troglitazone	2015
Evaluation of the synuclein-γ (SNCG) gene as a PPARγ target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue. PloS one, 2015, Volume: 10, Issue:3 Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; gamma-Synuclein; Ganglia, Spinal; Humans; Hypoglycemic Agents; Male; Mice; Middle Aged; Neoplasm Proteins; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Protein Binding; Rosiglitazone; Sensory Receptor Cells; Thiazolidinediones; Transcription, Genetic; Transcriptional Activation	2015
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:7 Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucocorticoids; Hydrolysis; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides; Troglitazone	2015
LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. Journal of pharmaceutical and biomedical analysis, 2015, Volume: 111 Topics: Acetates; Acetonitriles; Animals; Chromatography, Liquid; Dried Blood Spot Testing; Hematocrit; Ions; Limit of Detection; Pioglitazone; Rats; Rats, Wistar; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazolidinediones	2015
Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists. Archiv der Pharmazie, 2015, Volume: 348, Issue:6 Topics: 3T3-L1 Cells; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Female; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Molecular Docking Simulation; Molecular Structure; Pioglitazone; PPAR gamma; Protein Binding; Rats, Wistar; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transfection	2015
Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes. Molecular and cellular biochemistry, 2015, Volume: 405, Issue:1-2 Topics: Animals; Cells, Cultured; Collagen; Mice; Phosphorylation; Pioglitazone; Podocytes; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Smad2 Protein; Smad3 Protein; Thiazolidinediones; Transforming Growth Factor beta; Up-Regulation	2015
Effect of pioglitazone medication on the incidence of dementia. Annals of neurology, 2015, Volume: 78, Issue:2 Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; Germany; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Protective Factors; Rosiglitazone; Thiazolidinediones	2015
How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7 Topics: Cardiovascular Diseases; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Utilization; Humans; Hypoglycemic Agents; Medicaid; Pioglitazone; Reimbursement Mechanisms; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2015
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 2015, Volume: 51 Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Antihypertensive Agents; Arteries; Cyclic GMP; Dose-Response Relationship, Drug; Drug Interactions; Glucose; Glycolysis; Hypoglycemic Agents; In Vitro Techniques; Metformin; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase 5 Inhibitors; Pioglitazone; Rats; Rosiglitazone; Sildenafil Citrate; Tail; Thiazolidinediones; Vasodilator Agents	2015
Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:8 Topics: 11-beta-Hydroxysteroid Dehydrogenases; 3T3-L1 Cells; Adipogenesis; Animals; Diabetes Mellitus, Experimental; Glucose; Mice; Mice, Obese; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2015
PPARγ Agonists Attenuate Palmitate-Induced ER Stress through Up-Regulation of SCD-1 in Macrophages. PloS one, 2015, Volume: 10, Issue:6 Topics: Animals; Apoptosis; Cell Line; Endoplasmic Reticulum Stress; Gene Expression Regulation; Macrophages; Mice; Palmitates; Pioglitazone; PPAR gamma; Rosiglitazone; Stearoyl-CoA Desaturase; Thiazolidinediones; Up-Regulation	2015
Detection of structurally similar adulterants in botanical dietary supplements by thin-layer chromatography and surface enhanced Raman spectroscopy combined with two-dimensional correlation spectroscopy. Analytica chimica acta, 2015, Jul-09, Volume: 883 Topics: Chromatography, Thin Layer; Colloids; Dietary Supplements; Drug Contamination; Hypoglycemic Agents; Lasers; Pioglitazone; Reproducibility of Results; Rosiglitazone; Silver; Spectrum Analysis, Raman; Thiazolidinediones	2015
G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. The Journal of biological chemistry, 2015, Aug-07, Volume: 290, Issue:32 Topics: Cell Line; DNA; E1A-Associated p300 Protein; Endothelial Cells; Gene Expression Regulation; Genes, Reporter; Humans; Hypoglycemic Agents; Ligands; Luciferases; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR gamma; Primary Cell Culture; Protein Binding; Receptor Cross-Talk; Receptors, G-Protein-Coupled; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones; Transcription Factors; Transcription, Genetic	2015
Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. Drug safety, 2015, Volume: 38, Issue:9 Topics: Databases, Factual; Edema; Ethnicity; Furosemide; Heart Failure; Hospitalization; Humans; Pioglitazone; Polymorphism, Genetic; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2015
PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice. British journal of pharmacology, 2016, Volume: 173, Issue:2 Topics: Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Hippocampus; Male; Mice; Mice, Inbred C57BL; Microvessels; Neuronal Plasticity; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Transport; Rosiglitazone; Thiazolidinediones	2016
Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ. Biochemistry, 2015, Nov-17, Volume: 54, Issue:45 Topics: Benzamides; Carotid Artery Diseases; Cell Differentiation; Cells, Cultured; Chemotaxis; Combined Modality Therapy; Depression, Chemical; Diabetes Mellitus, Type 2; Down-Regulation; Endarterectomy, Carotid; Gene Expression Regulation; Humans; Macrophages; Pioglitazone; PPAR alpha; PPAR gamma; Pyridines; Receptors, CXCR; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones	2015
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ. PloS one, 2015, Volume: 10, Issue:10 Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Male; Mouth Neoplasms; Pioglitazone; PPAR gamma; Quinolones; Rats; Rats, Inbred F344; Rosiglitazone; Thiazolidinediones	2015
AMP-Activated Protein Kinase Mediates the Antiplatelet Effects of the Thiazolidinediones Rosiglitazone and Pioglitazone. Molecular pharmacology, 2016, Volume: 89, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Male; Pioglitazone; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2016
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. Medicine, 2016, Volume: 95, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms	2016
Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF‑7 cells by reducing FGF4 protein expression. Molecular medicine reports, 2016, Volume: 13, Issue:4 Topics: Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Conditioned; Cytokines; Down-Regulation; Fibroblast Growth Factor 4; Gene Expression Regulation; Humans; Ki-67 Antigen; MCF-7 Cells; Mesenchymal Stem Cells; Pioglitazone; Proliferating Cell Nuclear Antigen; Rosiglitazone; Thiazolidinediones	2016
Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ (Clinical research ed.), 2016, Mar-30, Volume: 352 Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; General Practice; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms	2016
CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes care, 2016, Volume: 39, Issue:11 Topics: Aged; Blood Glucose; Cytochrome P-450 CYP2C8; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Pharmacogenetics; Pioglitazone; Polymorphism, Single Nucleotide; Rosiglitazone; Scotland; Thiazolidinediones; Treatment Outcome; White People	2016
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. Diabetes research and clinical practice, 2016, Volume: 116 Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones	2016
A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:9 Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides	2016
Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health policy (Amsterdam, Netherlands), 2016, Volume: 120, Issue:12 Topics: Denmark; Diabetes Mellitus, Type 2; Drug Interactions; Drug Labeling; Drug Prescriptions; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Germany; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2016
Thiazolidinediones abrogate cervical cancer growth. Experimental cell research, 2017, 04-15, Volume: 353, Issue:2 Topics: Animals; Cell Differentiation; Cell Proliferation; Complement Factor D; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mice; Papillomaviridae; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Uterine Cervical Neoplasms	2017
Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions. Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:6 Topics: Cryopreservation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Kinetics; Pioglitazone; Rifampin; Rosiglitazone; Thiazolidinediones	2017
The effects of troglitazone on AMPK in HepG2 cells. Archives of biochemistry and biophysics, 2017, 06-01, Volume: 623-624 Topics: AMP-Activated Protein Kinases; Chromans; Diabetes Mellitus, Type 2; Enzyme Activation; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Phosphorylation; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone	2017
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Experimental physiology, 2017, 08-01, Volume: 102, Issue:8 Topics: Acetophenones; Adipose Tissue; Animals; Anion Transport Proteins; Diet, High-Fat; Hypoglycemic Agents; Insulin; Insulin Resistance; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Pioglitazone; PPAR gamma; Proprotein Convertase 2; Rosiglitazone; Thiazolidinediones	2017
Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. Pharmacoepidemiology and drug safety, 2017, Volume: 26, Issue:11 Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Interrupted Time Series Analysis; Legislation, Drug; Metformin; Patient Safety; Pharmacoepidemiology; Pioglitazone; Republic of Korea; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2017
Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection. Journal of controlled release : official journal of the Controlled Release Society, 2017, Oct-28, Volume: 264 Topics: Adiponectin; Adipose Tissue; Adult; Animals; Anti-Inflammatory Agents; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Drug Carriers; Humans; Jugular Veins; Monocytes; Myocytes, Smooth Muscle; Pioglitazone; Rosiglitazone; Swine; Thiazolidinediones; Tumor Necrosis Factor-alpha	2017
Effects of thiazolidinedione in patients with active bladder cancer. BJU international, 2018, Volume: 121, Issue:2 Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neoplasm Staging; Pioglitazone; Retrospective Studies; Rosiglitazone; Survival Rate; Thiazolidinediones; Urinary Bladder Neoplasms	2018
Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation. Journal of neuroinflammation, 2017, Sep-08, Volume: 14, Issue:1 Topics: AIDS Dementia Complex; Animals; Encephalitis; HIV-1; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones	2017
A Combination of the Aerosolized PPAR-γ Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats. Neonatology, 2018, Volume: 113, Issue:4 Topics: Administration, Inhalation; Animals; Animals, Newborn; Biomimetic Materials; Cell Differentiation; Female; Hyperoxia; Lung; Lung Injury; Male; Pioglitazone; PPAR gamma; Protein Precursors; Proteolipids; Pulmonary Alveoli; Rats; Rats, Sprague-Dawley; Rosiglitazone; Surface-Active Agents	2018
A Pharmacogenetic Approach to the Treatment of Patients With Diabetes, 2018, Volume: 67, Issue:6 Topics: Adolescent; Adult; Amino Acid Substitution; Binding Sites; Female; Gene Expression Regulation; Genes, Reporter; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Lipodystrophy, Familial Partial; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Mutation, Missense; Pharmacogenetics; Pioglitazone; PPAR gamma; Protein Conformation; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Young Adult	2018
Palmitoyl lactic acid induces adipogenesis and a brown fat-like phenotype in 3T3-L1 preadipocytes. Biochimica et biophysica acta. Molecular and cell biology of lipids, 2018, Volume: 1863, Issue:7 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue, Brown; Animals; Cell Differentiation; Lactic Acid; Lipid Droplets; Mice; Obesity; Palmitates; Phenotype; Pioglitazone; PPAR gamma; Rosiglitazone	2018
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12 Topics: Abscess; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incidence; Liver Abscess; Male; Metformin; Middle Aged; National Health Programs; Pioglitazone; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones; Treatment Outcome	2018
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Humans; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Rosiglitazone; Young Adult	2019
A comprehensive evaluation of anti-diabetic drugs on nuclear receptor PXR platform. Toxicology in vitro : an international journal published in association with BIBRA, 2019, Volume: 60 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Chlorocebus aethiops; Cytochrome P-450 CYP3A; Drug Interactions; Glucuronosyltransferase; Humans; Hypoglycemic Agents; Pioglitazone; Pregnane X Receptor; RNA, Small Interfering; Rosiglitazone	2019
Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model. Scientific reports, 2019, 07-01, Volume: 9, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Brain; Cells, Cultured; Disease Models, Animal; HIV Core Protein p24; HIV Infections; HIV-1; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Neuroglia; Nitric Oxide Synthase Type II; Oxidative Stress; Pioglitazone; PPAR gamma; Rosiglitazone; Tumor Necrosis Factor-alpha	2019
The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular diabetology, 2020, 02-25, Volume: 19, Issue:1 Topics: Adult; Aged; Arrhythmias, Cardiac; Databases, Factual; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Medicaid; Middle Aged; Pioglitazone; Protective Factors; Risk Assessment; Risk Factors; Rosiglitazone; Time Factors; Treatment Outcome; United States	2020
Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation. Clinical and translational gastroenterology, 2020, Volume: 11, Issue:4 Topics: Biopsy; Budesonide; Cells, Cultured; Drug Evaluation, Preclinical; Eosinophilic Esophagitis; Esophagus; Fibrosis; Gene Expression Regulation; Humans; Interleukin-4; Myofibroblasts; Pioglitazone; PPAR gamma; Primary Cell Culture; Rosiglitazone; Signal Transduction; Transforming Growth Factor beta1	2020
Antenatal PPAR-γ agonist pioglitazone stimulates fetal lung maturation equally in males and females. American journal of physiology. Lung cellular and molecular physiology, 2020, 09-01, Volume: 319, Issue:3 Topics: Animals; Animals, Newborn; Cell Differentiation; Female; Lung; Male; Pioglitazone; PPAR gamma; Pulmonary Alveoli; Rats, Sprague-Dawley; Rosiglitazone; Sex Characteristics; Sexual Maturation	2020
Capsaicin up-regulates pro-apoptotic activity of thiazolidinediones in glioblastoma cell line. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 132 Topics: Apoptosis; Brain Neoplasms; Capsaicin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Humans; Ligands; Pioglitazone; PPAR gamma; Rosiglitazone; TRPV Cation Channels; Up-Regulation	2020
4-thiazolidinone-based derivatives rosiglitazone and pioglitazone affect the expression of antioxidant enzymes in different human cell lines. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139 Topics: A549 Cells; Antioxidants; Apoptosis; Caco-2 Cells; Caspase 3; Cell Line; Cell Line, Tumor; Humans; Neoplasms; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidines	2021
PPAR-γ alleviates the inflammatory response in TNF-α-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis. Acta pharmacologica Sinica, 2023, Volume: 44, Issue:2 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Fibroblasts; Humans; Inflammation; Mice; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53	2023
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry. Methods in molecular biology (Clifton, N.J.), 2024, Volume: 2737 Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide	2024